Insulet 2022 Sustainability Report2022
Sustainability Report1Insulet 2022 Sustainability Report

Table of Contents
Message From the CEO

3

Message From the CSO

4

About Insulet

52022 Performance8

Our Approach to Sustainability

10

Resilient Operations

20

Sustainable Product Innovation

26

People and Communities

34

Appendix472

Insulet 2022 Sustainability Report

Message From the CEO
At Insulet, every action we take centers on our mission—
to improve the lives of people with diabetes. When I
stepped into my role as Insulet’s President and Chief
Executive Officer in June 2022, I felt incredibly
privileged to serve a company built on such a
powerful mission. I know this sentiment resonateswith our employees, many of whom have a personalconnection to diabetes. Our achievements in 2022
showcased this dedication to the diabetes community, which
was further exemplified by the Omnipod® 5 Automated Insulin Delivery
System (Omnipod 5). This flagship product, launched in the U.S. in 2022,
automatically adjusts insulin delivery based on readings from an integrated
continuous glucose monitor. It’s immensely inspiring to hear users andcaregivers tell us how this product has changed their lives for the better.
Omnipod 5 and the continued global success of our other Omnipod®
products allowed us to serve more people than ever in 2022. As we grow,
Insulet continues to set the standard for customer-centric designs andapproaches. At the same time, we also thoughtfully integrate sustainability
into our strategic decision-making as we grow our business. We incorporate
sustainable practices while continuing to improve health outcomes andaccess to our products. While we expand our operations globally, we harness
opportunities for positive environmental, social, and governance impacts
that accelerate our business and growth strategy.

For instance, our regional product takeback programs allow customers inseveral countries to return their used Pods to us for responsible disposal.
In 2022, we piloted a takeback program in the U.S. and are continuously
exploring further opportunities to reduce our environmental footprint.
As we foster deep ties with our communities, we also strive to encourage
collaboration among our own teams. Across the globe, we embrace
opportunities to connect through events promoting diversity, equity, andinclusion, quality and compliance, and innovation.
Through our commitment to sustainable growth, consumer safety remains
our top priority. We value the trust our customers place in us to deliver safe,
effective, and accessible health outcomes. In 2022, we voluntarily took action
to resolve product issues, exemplifying our customer-centric approach. I also
see this focus in our advocacy efforts, where our teams champion policies
and utilize strategic partnerships that enhance global accessibility to ourlife-changing products.
In the 2022 Sustainability Report, I’m proud to share how Insulet continues torevolutionize health outcomes and drive a sustainable future that optimizes
value for our customers, communities, investors, and employees. Thank you
for your support as we continue to advance sustainable business and change
lives for the better.
Sincerely,
Jim Hollingshead
President and Chief Executive Officer3

Insulet 2022 Sustainability Report

Message From the CSO
Insulet’s commitment to sustainability expanded withincreased momentum in 2022. We developed greater
insights from our data, built on ideas generated from
employees and other stakeholders, and learned more
about what excites our customers. As we continue toembed sustainability into our business processes anddecisions, we are seeing how this shift in mindset will
accelerate our progress to a sustainable future.
 hile expanding our product portfolio, customer base, and global reach, weWworked to grow responsibly and minimize our environmental footprint. We areproud of the work we completed to drive resilient operations as we evolved our
climate strategy and management systems for a socially responsible supply base.
z e developed our first disclosure index in alignment with recommendations
W
from the Task Force on Climate-Related Financial Disclosures.

z e continued to invest in renewable energy. In 2022, our on-site solarWpanels at our Acton, Massachusetts headquarters generated 937
megawatt hours of renewable energy, an almost 20% increase over 2021.

z e promoted sustainable practices in our supply chain by increasing
W
training on our Supplier Code of Conduct and completing our first socialand environmental supply base risk assessment.

In 2022, we continued to focus on delivering customer-centric designs for
our Omnipod products that reflect our priorities of quality, safety, andsustainability. Sustainable product innovation is becoming more embedded
in our product design across the lifecycle as we look to reduce ourconsumption of natural resources, keep materials in use longer, and focus
on environmentally friendly packaging.
z

 e reaffirmed our commitment to quality through adherence to leadingW
standards, comprehensive employee training—including 7,000 training
hours during quality and compliance week—and swift responses tomitigate any quality risks.

z e incorporated Australia into our product takeback program in 2022W
and continue to pilot new methods for takeback and disposal in the U.S.

z

 e redesigned our Omnipod 5 starter kit packaging to enhance recyclabilityW
and reduce emissions from packaging by 77% once launched in 2023.

We aspire to create positive social impact and advance inclusivity for ourcustomers, employees, and communities. We continue to support ouremployee health and wellness with flexible working arrangements andpromote an inspiring culture as we grow globally.
z e increased the representation of U.S. employees who identify asW
ethnically diverse from 33% in 2021 to 37% in 2022.

z e formed our eighth Employee Resource Group (ERG), the Asian andW
Pacific Islander ERG, in 2022.

z e created a new activation in the popular Nintendo® video gameW
Animal Crossing™: New Horizons that celebrates diversity and promotes
inclusivity for people with diabetes[1].

Insulet is a dynamic company with an impactful purpose, fueled by ourinnovative spirit. As we strive to serve more people in the global diabetes
community, we’re focused on advancing a more sustainable future for ourpeople and our planet. I am pleased to present our progress in Insulet’s
2022 Sustainability Report.
Sincerely,
Lisa Brady
Vice President, Global Sustainability and Chief Sustainability Officer[1] Insulet Corporation is not affiliated, endorsed, or otherwise associated with Nintendo Co., Ltd.,
Nintendo of America, Inc. or any of their subsidiaries or affiliates. The names Animal Crossing™:
New Horizons, Nintendo® and Nintendo Switch™, and their related marks and logos aretrademarks or registered trademarks of their respective owners.

4Insulet 2022 Sustainability Report

Omnipod 5 AutomatedInsulin Delivery System
Omnipod 5 is the first and only tubeless AID system in the U.S. that
integrates with the Dexcom G6® Continuous Glucose Monitoring(CGM) System[1] to measure interstitial fluid and automaticallyadjusts insulin delivery to manage glucose with no multiple daily
injections and zero fingersticks.[2] Located on the Pod, theembedded AID algorithm predicts glucose levels into the future
and automatically adjusts insulin dosing to help protect againsthigh and low glucose levels during the day and night. Users have[3]

the option of using the Omnipod 5 App on a compatible
smartphone or the separate Omnipod 5 Controller.[4]The U.S. FDA cleared Omnipod 5 for commercial distribution in
January 2022 for people with type 1 diabetes aged six years andolder. In August, we expanded Omnipod 5’s U.S. indication for use
by individuals aged two years and older. In
September, we received CE Marking under
the EU MDR for Omnipod 5 for individuals
aged two years and older with type 1
diabetes. In 2022, we presented andpublished results of our feasibility studies toevaluate the use of Omnipod 5 in adults
with insulin-intensive type 2 diabetes.
Overall, research demonstrates significant
improvements in HbA1c and improved Timein Range (TIR) with the use of Omnipod 5.

About Insulet
Insulet Corporation (Insulet or the Company) (NASDAQ: PODD),
headquartered in Acton, Massachusetts, is an innovative medical devicecompany dedicated to simplifying life for people with diabetes and otherconditions through its Omnipod® product platform. The Omnipod® Insulin
Management System (Omnipod) provides a unique alternative to traditional
insulin delivery methods. With its simple, wearable design, the disposable
Pod provides up to three days of non-stop insulin delivery, without the needto see or handle a needle. Insulet’s latest innovation, Omnipod 5, is a
tubeless automated insulin delivery (AID) system, is integrated with acontinuous glucose monitor to manage blood sugar without multiple daily
injections and fingersticks, and is fully controlled by a compatible personalsmartphone.[5] Insulet also leverages the unique design of its Pod by tailoring
its Omnipod technology platform for the delivery of non-insulin
subcutaneous drugs across other therapeutic areas. For more information
about the Company, please see the Insulet website.
[1] The
Dexcom G6 requires a separate prescription and is sold separately. The Dexcom App isrequired to control the Dexcom G6.
[2] F ingersticks are required for diabetes treatment decisions if symptoms or expectations do notmatch readings.
[3] B rown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with
T1D aged 6–70 yrs [adults/adolescents (n= 128; aged 14–70 yrs) children (n=112; aged 6–13.9 yrs)].
Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid
closed-loop phase. Mean overnight time > 180 mg/dL (12AM-6AM) as in adults/adolescents andchildren, ST vs. 3-mo Omnipod 5: 32.1% vs. 20.7%; 42.2% vs. 20.7%, P<0.0001, respectively. Meanday time >180 mg/dL (6AM–12AM) in adults/adolescents and children, ST vs. 3-mo Omnipod 5:
32.6% vs. 26.1%; 46.4% vs. 33.4%, P<0.0001, respectively. Median overnight time in <70 mg/dL(12AM–6AM) in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.07% vs. 0.82%,
P<0.0001; 0.78% vs. 0.78%, P=0.0456, respectively. Median day time <70 mg/dL (6AM–12AM) in
adults/adolescents and children, ST vs. 3-mo Omnipod 5: 1.91% vs. 1.08%, P<0.0001; 1.17% vs.
1.62%, P=0.2545, respectively. Outcomes measured by CGM, and; Sherr JL, et al. Prospective trial
in 80 participants with T1D aged 2–5.9 yrs. Study included a 14-day standard therapy (ST) phasefollowed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean overnight time > 180
mg/dL (12AM–6AM) as measured by CGM: ST = 38.4%, 3-mo Omnipod 5 = 16.9%, P<0001. Mean
daytime > 180 mg/dL (6AM–12AM) as measured by CGM: ST = 39.7%, 3-mo Omnipod 5 = 33.7%,
P<0001. Median overnight time in < 70 mg/dL (12AM–6AM) as measured by CGM: ST = 3.41%,
3-mo Omnipod 5 = 2.13%, P=0.0185. Median daytime < 70 mg/dL (6AM–12AM) as measured by
CGM: ST = 3.44%, 3-mo Omnipod 5 = 2.57%, P=0.0799. Outcomes measured by CGM.
[4] F
 or a list of compatible smartphone devices visit omnipod.com/compatibility.
[5] F ingersticks are required for diabetes treatment decisions if symptoms or expectations do notmatch readings.

Our Mission
To improve the lives of people with diabetes.

Our Vision
We create innovative technology that allows
people living with diabetes globally to enjoy
simplicity, freedom, and healthier lives.

Innovative Spirit: Creating innovative solutions that simplify
life through advanced technology and clinical expertise

Global Pioneer: Breaking down barriers to ensure global
affordable access and better outcomes for more people withdiabetes around the world

Customer-Centric: Providing best-in-class service and support
and generating insight-driven programs from a relentlesspassion for improving the lives of people with diabetes

5Insulet 2022 Sustainability Report

Our Products
Omnipod DASHThe Omnipod DASH® Insulin Management System(Omnipod DASH), launched in the U.S. in 2018 and in our

Omnipod products are continuous insulin delivery systems that provide all
the benefits of insulin pump therapy in a unique way. Pod therapy consistsof two primary parts:zPod: The tubeless, waterproof[1] Pod provides automated, virtually
pain-free insertion, can be worn in multiple locations directly on thebody, and delivers precise, personalized doses of insulin for up to
three days. We also leverage the unique design of our Pod by tailoring
the Omnipod technology platform for the delivery of non-insulin
subcutaneous drugs across other therapeutic areas.

z ersonal Diabetes Manager (PDM) or Controller: The handheld PDMPor Controller is a wireless, handheld device that programs the Pod withthe user’s personalized insulin-delivery instructions and wirelessly
monitors the Pod’s operation.

international markets in 2019, is built upon the success ofearlier generations of our Omnipod portfolio. Omnipod
DASH embeds secure Bluetooth® technology into the Pod
and features a modernized touchscreen PDM. Users canquickly and easily monitor real-time glucose data andinsulin history on their smartphone through two freemobile applications offered in the U.S. (Omnipod
DISPLAY and Omnipod VIEW ).
®

®

Designed to fit within the daily routines of users, Omnipod provides uniquebenefits compared to other currently available types of insulin therapy,
such as multiple daily injections (MDI) and traditional and automated insulindelivery pumps. The use of the Omnipod systems by individuals with either
type 1 or type 2 diabetes across all age groups is associated with improved
glycemic control and reduced frequency and severity of hypoglycemic episodes.
Furthermore, our innovative pay-as-you-go model, available in the U.S. and otherselect countries, offers customers a monthly, commitment-free cost structurethat simplifies payments and provides pump therapy at low or no up-front cost.
The majority of U.S. customers who use this model through the pharmacy
channel pay a copay of less than $50 USD per month. For more information,please see the Value, Affordability, and Accessibility section of this report andthe Insulet website, which was refreshed in 2022 to reflect our new branding.
We also continue to advance our product offerings to meet customer needs. In
November 2022, we submitted our 510(k) application to the U.S. Food and Drug
Administration (FDA) for a basal-only Pod for individuals with type 2 diabetes
which could serve over three million people in the U.S. Many people with type 2
diabetes follow a basal-only insulin regimen, which utilizes long-acting insulin tobring down high-resting blood glucose levels. We believe that this product, once
released, will expand the population of people with diabetes that we are
privileged to serve. Looking ahead, we are eager to continue working with ourregulatory stakeholders to bring this product to market.

[1] The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Personal Diabetes Manager
and Controller are not waterproof.

The Evolution of Omnipod
2022

2005
FDA Clearance andCommercial Launch:
Omnipod (Generation 2)

2000
Insulet Founded

2011

2018

Began Canadian
Distribution

U.S. Launch: Omnipod
DASH (Generation 4)

FDA Clearance, U.S.
Launch, and European
Union (EU) Medical
Device Regulation (MDR)
Approval: Omnipod 5 AID
System (Generation 5)

FDA Clearance: Omnipod(Generation 1)

Began European
Distribution

U.S. Launch: Omnipod(Generation 3)

Began Australian and Middle
Eastern Distribution

2003

2010

2013

2021

6

Insulet 2022 Sustainability Report

Locations

Industry Association Memberships

We are expanding our global reach with offices in nine countries, and our products are accessible in 24 countries in North America, Europe,
the Middle East, and Asia Pacific. Every day, we are actively working to reach more customers around the world.

Our memberships in the following associations reflect our continued
commitment to improving access to innovative medical technology andmaintaining the highest standards of conduct:Insulet’s manufacturing expertise is a competitive advantage. We have made significant investments over the years to expand our operational
excellence and establish redundant manufacturing capabilities, which have prevented global supply chain issues from impacting ourcustomers. In 2022, we acquired assets from Dynalloy, Inc., now known as Insulet Irvine, related to the design and manufacturing of wire
assemblies which drive the pump within Omnipod. Owning this differentiating technology secures our development and manufacturing
capabilities, further strengthening our production capabilities, efficiency, and operational excellence.

Map Locations
OfficeInsulet-Owned Manufacturing

Distribution Center

MunichUtrecht

Mississauga,
Ontario

Irvine, CA
San Diego, CA

LondonParisActon, MA(Headquarters)

Kunshan, Jiangsu

Nashville, TN

Tijuana

Shenzhen, Guangdong

Dubai

z

 A Medical Device Industry Council (MassMEDIC), Massachusetts,
M
U.S.: Our Vice President (VP) of Global Sustainability and Chief
Sustainability Officer (CSO) sits on MassMEDIC’s Board of Directorsz edical Device Innovation Consortium (MDIC), U.S.: Our CEO sitsM
on MDIC’s Board of DirectorszAssociation of British HealthTech Industries (ABHI), United KingdomzDiabetes Technology Access Coalition, U.S.

z

Diabetes Training and Technical Assistance Center (DTTAC), U.S.

z

MedTech EuropezMedTech CanadazAsia Pacific Medical Technology Association (APACMed), Asia PacificzMecomed, Middle East and AfricazBundesverband Medizintechnologie e.V (BVMed), GermanyzSPECTARIS, Germanyz yndicat National de l’Industrie des Technologies Médicales
S(SNITEM), FrancezAUSTROMED, AustriazSwiss Medtech, SwitzerlandzDiagnostica Associatie Nederland (DIAGNED), Netherlands

Johor Bahru, Malaysia[1]

Sydney[1] Insulet’s Malaysia location is currently
under construction.

 he Advanced Medical Technology Association (AdvaMed), U.S.: Our
T
Chief Executive Officer (CEO) sits on AdvaMed’s Board of Directors

Countries Where Omnipod Was Sold in 2022

Waalwijk

Salt Lake City, UTz7

Insulet 2022 Sustainability Report

2022 Performance

Driving growth across our business for all stakeholders

Key Accomplishments
Strategic

Markets

People and Communities

360,000

Achieved public subsidy

27 hours

estimated active customers globally using Omnipod

for patient coverage in Australia, Croatia, Greece,and Qatar for Omnipod DASHof training per employee, including contractors, on average

Received U.S. FDA clearance of Omnipod 5 AID System for people
with type 1 diabetes aged two and older and achieved fullOmnipod 5 U.S. launch

Launched Omnipod DASH
in Saudi Arabia and the United Arab Emirates

67%
gender, racial, and/or ethnic diversity on our Board of Directors

23%
total Omnipod revenue growth

Resilient Operations

Sustainable Product Innovation

937 megawatt hours~6 million Pods

(MWh) of renewable energy generated through our on-site solar
panels in Acton, Massachusetts

responsibly disposed of through product takeback programs

77%

96%
[1] Defined as the top 90% (increased from 80% in 2021) of Pod bill of materials, value-added
manufacturing, and PDM supplier spend. We engaged our suppliers to reach 100% training andcode acknowledgment for all 2022 applicable suppliers by early 2023.
[2] In-scope employees included any employees we determined regularly interact with Insulet suppliers.

of top-spend suppliers and 100% of in-scope employees
completed Supplier Code of Conduct training
[1]

[2]

estimated reduction in greenhouse gas (GHG) emissions
from Omnipod 5 starter kit packaging redesign8Insulet 2022 Sustainability ReportAwards and Ratings
Company

Responsibility

Workplace

Recognized as a

Named by Newsweek as one of

Recognized as a2022 Wearable
Technologies Honoree

America’s Most
Responsible Companies

Top Workplace USA 2022

Continued to achieve an

Ranked as one of theby the Consumer Technology Association’s CES
Innovation Awards for Omnipod 5

Received

Fierce Pharma’s Public
Relations Campaign AwardMSCI rating of AA

UK’s Best Workplaces

the second highest score on the rating scale, and placed in the
top 25% of healthcare equipment companies[2]Best Workplaces for Women, and Best Workplaces for Wellbeing
2022 (medium-size company) by Great Place to Work

Ranked as one offor promoting diversity and inclusion for people with diabetes
in Animal Crossing: New Horizons™[1]France’s Best
Workplaces 2022

Named to the(small company) by Great Place to Work

Boston Business Journal
2022 Middle Market List for revenue growth

Ranked as one ofGermany’s Best
Workplaces 2022

Recognized for

Global Enlightened
Growth LeadershipBest Practices in 2022 by Frost & Sullivan Instituteby Top Workplaces[1] Insulet Corporation is not affiliated, endorsed, or otherwise associated with Nintendo Co., Ltd.,
Nintendo of America, Inc. or any of their subsidiaries or affiliates. The names Animal Crossing™:
New Horizons, Nintendo® and Nintendo Switch™, and their related marks and logos aretrademarks or registered trademarks of their respective owners.
[2] M
 SCI’s ratings measure a company’s resilience to material environmental, social, andgovernance (ESG) risks(small company) by Great Place to Work

9

Insulet 2022 Sustainability Report

Our Approachto Sustainability
In This Section
Materiality and Stakeholder Engagement
Sustainability Strategy
Governance and Ethics

Introduction

Our Approach to Sustainability

Resilient Operations

Sustainable Product Innovation

People and Communities

Appendix10Insulet 2022 Sustainability Report

Materiality and Stakeholder Engagement
Understanding and addressing our key sustainability impacts

Materiality
We focus our sustainability strategy on the ESG topics that are most important to our business and account forour impacts on society, the economy, and the environment. In 2020, we utilized third-party expertise to conduct
our first materiality assessment, a research-based process to determine our most significant material ESG topics
with input from internal and external stakeholders.
Through our materiality assessment, we identified 23 ESG topics most impactful to our business and stakeholders.
This process was informed by interviews and surveys with employees, customers, suppliers, investors, payors,
healthcare professionals, and advocacy groups. The results of our materiality assessment enable us to concentrate
our management on key priorities, and our sustainability strategy and reporting efforts incorporate these topics.
We continuously evaluate our performance and plan to conduct materiality assessments at regular intervals toalign with our continued growth, our dynamic industry, and the evolving expectations of stakeholders. For a moredetailed description of our materiality assessment process, please visit our 2020 Sustainability Report.

Materiality Matrix

Highest Priority Material ESG Topics

Highest Priority Material ESG Topics

Definitions

Product Quality and Safety

Protecting customer health and safety by enforcing rigorous
quality assurance systems throughout the full lifecycle ofproducts, including design, sourcing, manufacturing, and sales.

Data Privacy and Cybersecurity

Deploying privacy and security systems and controls, andinvesting in people, process, and technology controls to ensurethat the privacy integrity, security, and accessibility of personal
data are not compromised.

Affordability and Accessibility

Ability to make products and therapies accessible to customers,
improving availability and affordability of products throughpartnerships, and investing in critical skills and infrastructure.

Governance and Ethics

Establishing clear governance processes, transparent reporting
structures, a well-defined code of conduct, and monitoring
systems to ensure personnel uphold the highest ethicalstandards in business operations and customer interaction.

Compliance and Anti-Corruption

Establishing clear leadership and accountability for compliancein line with applicable anti-corruption and anti-bribery laws andregulations, as well as rigorous auditing and monitoring processes.

Product Stewardship

Driving sustainable product design and packaging choices
and focusing on recycling/reuse options. Reducing theenvironmental impact and waste of products and making
products more efficient.

Customer Centricity

An unwavering commitment to improving the lives of people
with diabetes, with the best interests of our customers top ofmind in everything we do.

Importance to Stakeholders

Product Quality and Safety
Customer Centricity
Data Privacy and Cybersecurity
Workplace Healthand Safety

Inclusion and Diversity

Innovation

Human Rights
Stakeholder Management

R&D

Talent Management and Retention
Climate Change

Affordability and Accessibility
Governance and Ethics
Compliance and Anti-Corruption
Product StewardshipResponsible Supply Chain Management
Intellectual Property
Policy and
Advocacy

Community Engagement

Waste Management

Energy Management
Marketing Practices

Water Management

Importance to Business11

Insulet 2022 Sustainability Report

Stakeholder Engagement
Stakeholder feedback helps us understand our operating environment, increase our positive impacts, and orient our overall performance todeliver sustainable value. Through effective and regular engagement activities, we aim to better understand stakeholder interests, address
their concerns, and meet their expectations. We have identified key stakeholder groups who have a strategic connection to our operations
and contribute to the success of our business. Through this report, we continue to enhance stakeholder dialogue by transparently disclosing
progress and performance on key ESG topics that are most important to our stakeholders.

Stakeholder GroupKey ESG Topics

Methods of Engagement

Employees

Customer Centricity; Data Privacy and Cybersecurity; Diversity, Equity, and Inclusion; Innovation;
Product Quality and Safety; Talent Development

Global Town Hall meetings, ongoing Employee Engagement Surveys, intranet, virtual andin-person engagement events, employee sounding boards, trainings, monthly newsletter,virtual and in-person onboarding, social platforms, Employee Resource Groups

Customers

Affordability and Accessibility; Customer Centricity; Innovation; Product Quality and Safety;
Product Stewardship;

Surveys, focus groups, virtual and in-person product trainings

Communities

Customer Centricity; Data Privacy and Cybersecurity; Human Rights; Product Quality and Safety

Conferences, volunteering, donations

Suppliers and Business Partners

Climate Change; Customer Centricity; Diversity, Equity, and Inclusion; Governance and Ethics; Human
Rights; Innovation; Product Quality and Safety; Product Stewardship; Workplace Health and Safety

Audits, assessments, quarterly business reviews, supplier scorecards, training

Investors

Affordability and Accessibility; Climate Change; Diversity, Equity, and Inclusion; Governance andEthics; Product Quality and Safety; Talent Management and Retention; Workplace Health and Safety

Earnings calls and related reporting, industry and investor conferences, shareholder
meetings, press releases on material updates, U.S. Securities and Exchange Commission(SEC) filings, phone calls, meetings

Payors/Civil Servants/Ministers

Affordability and Accessibility; Climate Change; Customer Centricity; Data Privacy and Cybersecurity;
Human Rights; Innovation; Product Quality and Safety

Surveys, contract negotiations, meetings, dossier submissions, reimbursement proceduresand processes, horizon scanning exercises, industry association groups

Healthcare Professionals

Affordability and Accessibility; Customer Centricity; Data Privacy and Cybersecurity; Governance andEthics; Product Quality and Safety

Market research, product development, product trainings

Advocacy and Industry Groups

Affordability and Accessibility; Customer Centricity; Data Privacy and Cybersecurity; Diversity, Equity
and Inclusion; Human Rights; Policy and Advocacy; Product Quality and Safety

Meetings, conferences, focus groups, surveys

Regulatory and Government Bodies

Affordability and Accessibility; Compliance and Anti-Corruption; Data Privacy and Cybersecurity;
Governance and Ethics; Human Rights; Policy and Advocacy; Product Quality and Safety;
Workplace Health and Safety

Meetings, industry association groups, clearance and certification applications

12Insulet 2022 Sustainability Report

Sustainability Strategy
Guiding our responsible growth in alignment with our pillars
Our vision to “Deliver growth with purpose: innovating to
improve lives and preserve our planet” guides our efforts
to grow sustainably and maximize our positive impacts.
Our CSO and Global Sustainability function lead ourcomprehensive sustainability strategy, facilitate alignment
with our global growth plan, and establish thoughtful goals
to direct our progress. Underlying our comprehensive
approach, our three strategic sustainability pillars
concentrate on Resilient Operations, Sustainable
Product Innovation, and People and Communities.

Resilient Operations
Our Resilient Operations pillar defines our approach to sustainably managing
our operations and supplier relationships. We work to continue delivering
positive outcomes for the diabetes community in the face of changing global
conditions and mitigating our own impact on society and the environment.
We focus on preserving the health of the environment for our communities
and responsibly managing our supply chain, and we are actively exploring
additional opportunities to adopt targets that reflect our priorities.

Sustainable Product Innovation
Our Sustainable Product Innovation pillar recognizes that, as a leader in
revolutionary diabetes care, we can use our expertise to create products on
the cutting edge of environmentally conscious and inclusive design. We are
implementing product and packaging design initiatives that reduce resource
intensity, minimize waste, and contribute to a circular economy while
enhancing quality and customer-centric functionality.

People and Communities
Our People and Communities pillar focuses on maximizing positive social
impact by investing in our people and supporting the global diabetes
community. We strive to create an inclusive culture that enables all employees
to put their creative knowledge to use, grow their careers, and develop
the skills needed to advance the next generation of healthcare technology
workers. Leveraging our employee expertise, we fuel innovation that
improves the health of our communities and enhances product availability
and affordability to further simplify the lives of people with diabetes.

Our Focus for the Future
In 2022, we worked diligently to further embed our sustainability strategy
into our policies, processes, and goals. We began to evolve from setting aperformance baseline to operationalizing sustainability while still maintaining
our focus on enhancing transparency, preserving stakeholder trust, andcreating value. We continue to explore opportunities to establish ambitious
sustainability targets, and we plan to disclose our progress against thesegoals moving forward.
As exemplified by the COVID-19 pandemic, geopolitical developments,
and associated supply chain disruptions, a business continuity strategy
is essential to our sustainability efforts and our mission, because ourcustomers rely on Insulet products to effectively manage their diabetes.
In 2022, we enhanced our approach to business continuity by evaluating
critical business risks, understanding potential vulnerabilities, and reviewing
resilience protocols. To mitigate risks, we explore alternative productsolutions, establish supply reserves for critical materials, and protect
employee safety. Looking forward, we intend to continue to engage
leadership and external stakeholders to formalize our business continuity
program. For more information on how we embed resilience into our supply
chain, please see the Responsible Supply Chain Management section.

Our Sustainability Vision
Deliver Growth with Purpose: Innovating to
improve lives and preserve our planet

Resilient Operations
Growing responsibly across our businessand supply chain as we scale our operations
and minimize our environmental footprint

Sustainable Product Innovation
Ensuring environmentally conscious andinclusive design is embedded in our
products and packaging across the lifecycle

People and Communities
Improving lives of people in the global
diabetes community, driving an inclusive
culture, and inspiring social impact

13

Insulet 2022 Sustainability Report

Governance and Ethics
Maintaining the highest standards and upholding our values
Advancing sustainability and adhering to our mission
to improve the lives of people with diabetes requiresa strong foundation of governance and ethics. Robust
policies and expert leadership guide our path towardsustainable growth and foster a culture of ethicalbehavior throughout our operations. We diligently andproactively monitor issues of governance, ethics, andcompliance, knowing that our ability to maintain the trustof our stakeholders is key to building long-term value.

Governance Principles
We maintain strong governance policies and practices that drive our financial
success and responsible operations. Our principles for corporate governanceenable us to deliver on our commitments and maintain compliance with allapplicable laws and regulations.

Our Board of Directors
The Insulet Board of Directors oversees the strategic, financial, andmanagement policies of the Company. Taking an active role in the
Company’s strategic direction, the Board regularly educates itself on the
Company’s products, markets, customers, competition, and culture. The
Board assesses risk, evaluates management’s performance, plans for
successors, and provides overall guidance and direction to the Company.

Our Board believes that good governance requires not only an effective
set of specific practices, but also a culture of responsibility andaccountability throughout the organization. Good governance depends
on the quality of an organization’s leadership, and our Board is committed
to recruiting and retaining Directors and officers with proven leadershipability and personal integrity.
The Board, which consists of nine members, reflects diverse backgrounds,
expertise, and outlooks to meet stakeholder needs. The experience of Board
members spans academia, non-profit organizations, national public healthagencies, and public and private companies with global operations. At least
annually, the Board reviews the skills of its members and the overallcomposition of the Board to maintain a necessary breadth of knowledge
and perspective through a diversity of gender, race, ethnicity, age, andexperience. Currently, women constitute 56% of the Board, and the Board is67% diverse by gender, race, and/or ethnicity. The Board devotes significant
time on its agenda to reviewing and discussing the succession plans for the
CEO and each of their direct reports as part of building a diverse andinclusive workforce, and the Board also has plans in place in the event ofemergency succession. In 2022, the Board demonstrated strong leadershipcapabilities and strategically navigated a transition as Jim Hollingshead
succeeded Shacey Petrovic as President and CEO. We maintain welldeveloped processes to handle effective executive succession planning.
Our Corporate Governance Guidelines are designed to assist the Company
and the Board in implementing effective corporate governance practices.
To maintain alignment with governance best practices, the Board reviews
these guidelines annually, undertakes an annual self-evaluation to review
its structure, roles, processes, development, dynamics, and effectiveness,and communicates the results of the self-evaluations to relevant parties.

14

Insulet 2022 Sustainability Report

The Board has three standing committees each comprised entirely of
independent directors:zzz he Audit Committee oversees Insulet’s accounting and financial reportingTprocesses, audits of financial statements, and independent auditors.
 he Nominating, Governance, and Risk Committee identifies andTrecommends Board members, evaluates changes to the Corporate
Governance Guidelines, oversees regulatory compliance matters and ESG
initiatives, and discusses risk assessment and risk management policies.
 he Talent and Compensation Committee manages executiveT
compensation and oversees overall compensation programs as well as
the Company’s talent development and retention.

For more information on each committee, please see the committee charters
on our website.

ESG GovernanceAt the Board level, our Nominating, Governance, and Risk Committee oversees
our sustainability approach and management of material topics. Our Vice
President of Global Sustainability and CSO reports to the Senior Vice President(SVP), Global Operations, leads our sustainability strategy in alignment with
our global growth plan, and manages our ESG practices. The CSO reports to
the Nominating, Governance, and Risk Committee at least twice per year toreport our ESG progress and enhance the Board’s knowledge of sustainable
development. The Board may also review performance and updates for
specific material topics, such as climate change and product stewardship.
The Nominating, Governance, and Risk Committee also monitors our risk
assessment and management process. The Board receives regularpresentations on key enterprise risks and opportunities from our Chief
Compliance and Privacy Officer and head of Enterprise Risk. The Board
routinely meets with the members of management responsible for riskin their respective business functions. To continually inform our strategic
approach, our leadership communicates critical issues to the Board,
including risks related to compliance, data privacy, cybersecurity, talent,
supply chain, regulatory, product quality, and other ESG topics.

Our Governance Best PracticeszIndependent Chairman of the Boardz trong Board refreshment—attracted at least one new BoardS
member each year from 2014-2022z udit Committee, Talent and Compensation Committee, andA
Nominating, Governance, and Risk Committee each consist
solely of independent Directorsz irectors who do not receive a majority vote in an uncontested
Delection must promptly tender their resignation to the Board,which will consider whether to accept the resignationzRegular executive sessions of independent DirectorszExecutive and Director stock ownership guidelinesz o hedging or pledging of Insulet securities by executiveN
officers or Directors permittedzBoard adoption of proxy access Bylaw provisionsz

No shareholder rights plan (i.e., no “poison pill”)

zProactive year-round engagement with shareholders

Led by the CSO, our Global Sustainability function implements and evaluates
our overall sustainability strategy. This team continuously collaborates withall departments to facilitate the cross-functional communication necessary
to integrate sustainability into our business, measure our performance, andcontribute to positive impacts on our environment and communities. We also
proactively invest in sustainability initiatives and work to enhance capabilities
within our team to advance our ESG management and build on our progress.

15

Insulet 2022 Sustainability Report

Ethics, Compliance,
and Anti-Corruption
We strive to operate with integrity and transparency to preserve the trust
our customers place in us to deliver high-quality products with life-changing
impacts. Our culture of ethics impacts every interaction we have withcustomers, healthcare professionals, regulators, suppliers, investors, andcommunity members. As we grow and expand into new countries with newlaws and regulations, we maintain our commitment to upholding the highest
ethical standards at all levels of our organization.

Code of Business Conduct and Ethics
Our global Code of Business Conduct and Ethics outlines our expectations
for all employees, Directors, and officers to represent our values and upholdhuman rights. The Code is established by the Board and enforced by our
Chief Compliance and Privacy Officer. We expect everyone at Insulet toperform their duties in alignment with applicable laws and regulations
and to go beyond compliance, where necessary, to maintain the trust of
our stakeholders.
Our Code describes our values and outlines our policies regarding ethicalissues, including:z nti-Discrimination and Anti-Harassment: We do not tolerateA
discrimination or harassment against employees or job applicants
based on veteran status, race, color, religion, sexual orientation,
gender identity, age, national origin or ancestry, physical or mental
disability, or other consideration protected by law.

zCompetitive Practices: To promote fair competition, we will not tolerateor participate in any business conduct, transaction, or activity that
violates the antitrust, competition, or trade laws of any country in which
we do business.

zConflicts of Interest: Employees must avoid situations that present
a potential or actual conflict between their personal interests and theCompany’s interests.

z onfidentiality: We expect employees to only use proprietaryC
information for Company duties and to prevent the unauthorized
disclosure of proprietary information.

zHuman Rights: Our employees must promote a healthy, safe, andproductive work environment that upholds human rights and adheres
to all applicable labor and employment laws. For more information,please see the Human Rights section.

z

Political Contributions: All proposed political contributions with
Company funds must be approved by our Chief Compliance andPrivacy Officer.

Accountability
We encourage every employee to proactively ask questions, seek guidance,and report suspected violations of company ethics policies or any applicablelaws. Employees, customers, vendors, or other interested persons cananonymously report violations or express concerns through our confidential
Compliance and Ethics hotline and an online portal. The hotline is operated
by an independent company, is available toll-free from many countries, andis staffed 24/7 by multilingual case managers. Concerns and grievances canalso be directly reported to the General Counsel or the Chief Compliance andPrivacy Officer. We do not tolerate retaliation against employees forreporting suspected misconduct in good faith.

Our Compliance and Internal Audit functions regularly examine our Codeto incorporate emerging best practices. In 2022, we revised the Code toincorporate a more global approach and streamline language to focus on
our universal commitments. To guide our operations at a local level, we also
develop and circulate more detailed additions to our Code to account for
specific local regulations and concentrate on relevant risks. Additionally, in
2022, the Internal Audit function completed an audit of our U.S. Foreign
Corrupt Practices Act (FCPA) compliance procedures and developed an action
plan based on the results to further mitigate risks of bribery and corruption.
We intend to continue to conduct assessments of our most material
governance procedures and enhance our real-time risk monitoring capabilities.
We manage ethical conduct in our supply chain through our Supplier Code of
Conduct. For more information, please see the Responsible Supply Chain
Management section.

Employee Training
All employees and Board members are required to undergo ethics training
and certify adherence to our Code annually and when there are key updates
to our policies and procedures. Our goal is for 100% of employees to certify
compliance. In 2022, 100% of employees in North America completed training
and certified adherence, and we continue to advance tracking processes for
additional locations. Our ethics training is reinforced each year during our
Quality and Compliance Week, where we host lectures, workshops, andcommunity-building activities related to ethical issues in quality and compliance.

 t Insulet, we act with integrity and maintain theAhighest ethical standards in all that we do. We arecommitted to honest and responsible businessbehavior, and we ask our employees, suppliers,
distributors, healthcare professionals, customers,
and others to join us in this pursuit.
JIM HOLLINGSHEAD, PRESIDENT AND CEO

16

Insulet 2022 Sustainability Report

Data Privacy and Cybersecurity
We are proud to be innovators in digital health by designing our products tointegrate seamlessly with wireless systems, including compatible smartphones.
This allows our customers to manage and monitor their insulin delivery andglucose more effectively and conveniently. With increasing digitization comes
greater responsibility to maintain proper controls to protect our customers’
personal health data and defend our systems from external security threats.
Emphasizing prevention, we integrate cybersecurity and data privacy into our
product design and operations. We focus on continuous improvement tobetter protect our customers, employees, and business partners against
critical risks and to build resilience against online threats.

Data Privacy
Executing against our strategic commitment to privacy, our Privacy Office,
who reports to our Chief Information Officer, implements a standardized
approach that aligns with the increasingly diverse landscape of data privacy
laws in countries where our products are sold. We integrate strict regulatory
requirements into our global strategy, including the EU’s General Data
Protection Regulation (GDPR). In 2022, we expanded upon prior certifications
to conform to the International Organization for Standardization (ISO)/International Electrotechnical Commission (IEC) 27701:2019 certification, an
extension of ISO/IEC 27001, which is the international standard for privacy
information management. Obtaining this certification required an externalsurveillance audit and data privacy impact assessment, and our processes
performed strongly for both.
Prior to expanding operations in new countries, we assess local and national
data privacy laws to understand the requirements and determine how we
can enhance our procedures as needed. We conduct routine privacy impact
assessments to systematically analyze how personal information, including
personally identifiable health information, is collected, used, shared, andmaintained within our systems. The results of these privacy impact
assessments help us to identify and manage dynamic privacy risks associatedwith processing personal information of multiple constituencies, including
customer health data as well as personal information of employees, business
partners, and healthcare professionals.

We use a privacy management platform for our data privacy compliance anddata mapping. This platform also allows individuals to digitally request theirdata and exercise their privacy rights, which increases ease of access. For
more information on how we safeguard customers’ personal information,please see our Privacy Policy.

Product Security
The digital connectivity of our products enables simplicity and freedom in the
lives of people with diabetes. We diligently work to maintain the reliability of
our systems as our offerings become more complex. To preserve producteffectiveness and customer trust, our Global Information Technology (IT)team implements consistent product security measures across our businessand manages cybersecurity throughout the entire product lifecycle. We
conduct frequent product security testing exercises, including after any
software update. Our advanced encryption methods protect productconnection to wireless systems and use static code analysis and dynamic
testing to overcome vulnerabilities.
Our flagship innovation, Omnipod 5, incorporates high standards for
information management and cybersecurity. Allowing users to control the Pod
through a secure mobile application on a compatible smartphone, Omnipod 5
limits access to verified users, validates the reliability of the Omnipod 5 app,and confirms both the integrity and authentication of the smartphone device.
Additionally, Omnipod 5 has introduced X.509 certificate-based mutual
authentication that safeguards the dependability of the Controller and the
Pod by signing and verifying all critical commands sent to the Pod.
We monitor the global network of security standards to maintain best-in-classsecurity for our portfolio of products. In 2022, we exceeded the data security
standards required by the U.K. National Health Services Digital Security Toolkit
assessment and completed a promising preliminary assessment of ourperformance against Level 1 of the U.S. Cybersecurity Maturity Model
Certification (CMMC).

17

Insulet 2022 Sustainability Report

We currently align with the following frameworks:z

IEC 27000 series (ISO/IEC 27000) with ISO 27001:201 Information Security
Certification for all global products and servicesz ational Institute of Standards and Technology (NIST) Framework forN
Improving Critical Infrastructure Cybersecurityz DA’s Guidance “Content of Premarket Submissions for Management ofF
Cyber Security in Medical Devices” and “Post Market Management ofCybersecurity in Medical Devices”

zU.K. Cyber Essentials certification for Insulet IT processing systemszISO 27001 certification for all products and servicesz iabetes Technology Society (DTSec) Cybersecurity Standard forD
Connected Diabetes Device Security certification for Omnipod DASHz

 S EN ISO/IEC (British Standard and International Standard) ISO
B
27001:2017, which incorporates the requirements of BS ISO 27001:2013
to confirm information securityzISO/IEC 27701:2019 (International Standard), which expands the privacy
management section of ISO 27001 certification

Enterprise Security
We identify and mitigate enterprise security threats through our business-wide
Enterprise Risk Management (ERM) program and use this risk-based approach to
inform cybersecurity system controls and investments. Our Cybersecurity teamreports to the executive team on a quarterly basis and updates the Board of
Directors on our cybersecurity program and risks at least annually. To safeguard
the integrity of our operations, we integrate multiple layers of defense into ourIT systems and encrypt all Insulet laptops. Additionally, we conduct annual
tabletop exercises and penetration testing to evaluate our ability to rapidly
detect, respond to, and recover from an external cybersecurity threat. This
commitment to continuous improvement allows us to prevent data loss andsecure our operations against dynamic digital threats.

Employee Education and Training

Marketing Practices

To support preventive and defensive action, we encourage all employees toremain vigilant against digital threats. We pursue continuous training andemployee engagement to embed privacy and security best practices into
our culture. In 2022, we updated our cybersecurity and data privacy training
approach for new hires to improve accessibility and engagement, and we
added additional training modules for current employees. Our IT teams also
complete a training refresh to reinforce our essential security principles
whenever they embark on a major project.

Our stakeholders trust us to meet regulatory mandates and uphold our
ethical responsibility to implement transparent marketing practices andcommunications with healthcare professionals. We seek to continuously
improve our robust policies and adhere to the highest standards of integrity
to serve the diabetes community.

Across our organization, we send routine educational communications toemployees, operate an internal discussion board to promote cybersecurity
dialogue, and conduct periodic phishing tests to train employees to identify
and properly report malicious threats. Each year, our Privacy andCybersecurity teams host expert panels and collaborative training sessions
during our Quality and Compliance week. In 2022, we also facilitated asecurity poster campaign to foster employee dialogue on cybersecurity andpromote awareness of Insulet’s enhanced electronic processes forreporting incidents.

Culture of Ethics
Our Sales and Marketing Code of Ethics establishes mandatory standards forsales and marketing activities and governs all employee interactions withhealthcare professionals and customers. In the U.S., our Sales and Marketing
Code is based on the Code of Ethics of AdvaMed, our industry association, and isbuilt around six foundational values: innovation, education, integrity, respect,
responsibility, and transparency. We periodically update our Code to incorporate
evolving compliance and legal standards, and we verify our compliance programwith AdvaMed annually. Internationally, we utilize codes from regional industry
associations, such as MedTech Europe, MedTech Canada, and the Medical
Technology Association of Australia, to incorporate local requirements andstandards into our sales and marketing business practices.

18

Insulet 2022 Sustainability Report

We strictly follow our Code in communications regarding the safe andeffective on-label uses of our medical technology products. The Code restricts
communications about off-label uses or unapproved uses of approved
products. In alignment with the Code, we expect our employees to not interferewith the independent judgment of healthcare professionals and refrain fromusing unlawful or unethical inducements, whether offered to healthcare
professionals or customers with government-provided healthcare coverage.
Our Compliance function must approve all payments to healthcare
professionals to comply with industry and legal standards. We support
transparency efforts by disclosing payments as required by applicable
reporting regulations. The Code also requires compliance with anti-kickback
laws, anti-bribery laws, other applicable local, state, and federal regulations,and the AdvaMed Code of Ethics.

Transparent Marketing and Labeling Practices

We train all sales and marketing employees on our ethical marketing policies
and processes upon joining Insulet, and 100% of our sales and marketing
employees received onboarding or refresher training in 2022. Based on theirjob function, other employees may also receive training on our Sales andMarketing Code of Ethics upon hire and through an annual refresher course.
Employees who suspect any ethical violations must notify their supervisor,
the Company’s Chief Compliance and Privacy Officer, or the anonymous
Compliance and Ethics hotline or online portal.

Human Rights

Our customers and other stakeholders trust us to accurately describe our
products using appropriate, accurate, and inclusive language. Our Marketing,
Legal, and Regulatory Affairs functions collaborate to systematically review
and approve product marketing and labeling materials such as productclaims, label use, and direct-to-consumer advertising. We leverage a digitalmarketing approval process to review and track all promotional materials.
Across our global operations, we adhere to regulatory labeling requirementsin every market we serve and continually monitor our marketing practices tomaintain compliance. In 2022, we had no U.S. FDA 483 observations or
warning letters of incidents of non-compliance related to product labeling or
marketing communications.

Protecting human rights is a responsibility that Insulet takes seriously, andwe strive to protect the right for people to work in free and fair conditions.
We prohibit child labor, forced labor, human trafficking, and slavery in ouroperations and supply chain. Our Code of Business Conduct and Ethics andour Supplier Code of Conduct set the foundation for our human rights
commitment and compliance with applicable laws and regulations, including
the Australia Modern Slavery Act, California Supply Chains Act, and U.K.
Modern Slavery Act.
We demonstrate our commitment to upholding human rights byincorporating human rights considerations into our supplier selection andongoing monitoring processes. For example, as we evaluate potential
suppliers for our new manufacturing facility in Malaysia, our procurement
and sustainability teams are working closely to engage with prospective
suppliers on how they prevent and mitigate potential human rights risks,
including those related to forced labor, in their recruitment and employment
practices. For more information about our procurement, supplier auditing,and corrective action processes, please see the Responsible Supply Chain
Management section.

We released our first Human Rights Statement in 2023. This Statement
affirms our commitment to protecting the dignity of everyone who interacts
with an Insulet product, from component sourcing to customers managing
their diabetes. The principles in our Statement align with the United Nations
Universal Declaration of Human Rights, the International Labor
Organization’s (ILO) Declaration on Fundamental Principles and Rights at
Work, and the Ten Principles of the United Nations Global Compact. We arecommitted to respecting the rights of vulnerable groups, including minority
religious, political, racial, and ethnic communities; young workers; migrant
workers; people with disabilities; women; children; LGBTQ+ communities;
and others.

19Insulet 2022 Sustainability Report

Resilient Operations
As we expand our business globally, it is imperative that we remain focusedon advancing the sustainability of our operations and responsibly managing
our supply chain. Our customers trust us to deliver high-quality products
on time, and this mission is upheld by a foundation of resilient operations.
We strive to minimize our environmental footprint and use natural
resources efficiently while meeting the rising demand for our products.
Our commitment to addressing potential social and environmental impacts
also extends throughout our supply chain. Our efforts contribute to thereliability and resiliency of our operations, help enable responsible andefficient manufacturing, and minimize disruptions so we can deliver our
critical products that support customer health.
In This Section
Sustainable Operations
Supplier Responsibility

Podder Archie H. playing lacrosse

Introduction

Our Approach to Sustainability

Resilient Operations

Sustainable Product Innovation

People and Communities

Appendix20Insulet 2022 Sustainability Report

Sustainable Operations

GHG Emissions (Metric Tons of CO2e)[1]
Scope 1 (Direct)

Scope 2 (Indirect) Location Based

Fueling our growth with optimized resource use and transitioning to a low-carbon economy

Scope 2 (Indirect) Market Based
4,574

4,129
3,761

Aligned with our mission to improve the lives of people
with diabetes, we believe that the health of our society
is connected to the health of our planet. As we continue
to grow, we strive to responsibly manage our impacts
by preserving our natural environment and increasing
the efficiency of our processes. To improve businessresilience, address emerging regulations, and practiceresponsible corporate citizenship in a rapidly evolving
world, we work to minimize and manage our GHG
emissions, waste generation and disposal, energy use,
and water use throughout our operations. In 2022, we
focused on further integrating sustainability throughout
our culture and building out our capabilities to define
our ambitions and set comprehensive goals.

Climate Change andGreenhouse Gas Emissions
Insulet recognizes that climate change is one of the most significant issues
facing society and businesses today. We have a responsibility to reduce ourcontribution to climate change and to transparently report on our progress
and actions to mitigate climate-related risks. In addition to establishing ourmanagement framework, we are taking steps to understand and reduce the
GHG emissions generated in our own facilities.

2,903

Climate Change Strategy
Our Climate Change Statement forms the foundation of our climate strategy
and outlines our commitment to address the climate crisis. We havedeveloped a roadmap to incorporate the recommendations from the Task
Force on Climate-related Financial Disclosures (TCFD) into our reporting, andwe continue to align with TCFD guidance as we further evolve our approach.
In alignment with our roadmap, we are proud to present our inaugural TCFD
Content Index in this report, which describes our climate-related efforts infour thematic areas: governance, strategy, risk management, and metrics
and targets. By enhancing our climate disclosures, we aim to demonstrate
our thoughtful planning to mitigate risks and explore opportunities
associated with climate change and the transition to a low-carbon economy.
Leading our approach, our Nominating, Governance, and Risk Committee
oversees our management of climate change and regularly updates the full
Board of Directors. Our Global Sustainability team evaluates and prioritizes
opportunities to mitigate the effects of climate change, including efforts toimprove the efficiency of our facilities, reduce our GHG emissions, and utilize
renewable energy. We also continue to promote cross-functional
collaboration to effectively identify and manage climate-related risks that
could impact our operations.
We are setting our path to a net-zero economy. We are laying the
groundwork for better understanding our Scope 3 emissions, setting GHG
emissions reduction targets, increasing the adoption of renewable energy
and energy efficiency initiatives at our facilities, and further exploring
opportunities to mitigate our impacts. To improve our capacity for measuring
GHG emissions and tracking our progress toward future goals, we adopted a
new GHG management platform in 2022. This platform helps streamline ourdata collection process and allows our Global Sustainability team to invest
more time in planning emissions reduction strategies across our business.

3,556

2,273
1,709

1,455

1,417

2020

2021[2]2022[1] Insulet follows an operational control approach to calculate our emissions and utilizes theIntergovernmental Panel on Climate Change (IPCC) Fifth Assessment Report (AR5) global
warming potential (GWP) values. Our calculations include carbon dioxide (CO2), methane (CH4),
nitrous oxide (N2O), and refrigerants.
[2] Due to the acquisition of Insulet Irvine in 2022 and minor calculation methodology changes, thesevalues are a restatement of GHG emissions as disclosed in the 2021 Sustainability Report.

We must balance our commitment to managing our GHG emissions with ourcore mandates of quality, health and safety, and operational performance. In
2022, our Scope 2 emissions increased as we expanded production capacity byincorporating additional manufacturing equipment and improved production
quality by running machines with less downtime. Our 2022 Scope 2 emissions
also account for our Acton distribution center, constructed in 2022, and a fullyear of operation in our Tijuana facility, added in mid-2021. Our facility electricity
use increased due to more people working from our offices compared to theprevious two years. We also installed a heated sidewalk at our Acton facility toprevent icy walkways during hazardous weather. Although these initiatives
increased emissions, they also promoted employee health, safety, and wellbeing,
which are critical to our sustainability efforts. Additionally, our Scope 1 emissions
increased slightly due to the addition of company cars to our fleet to support our
European operations. Moving forward, we will continue to monitor our systems
and processes to increase efficiency and reduce emissions where possible.

21Insulet 2022 Sustainability Report

Reducing Transportation Emissions

Renewable Energy

To target climate-related risks in our supply chain, we strive to enhance
efficiency in our network and minimize emissions generated during thetransportation of our component parts and finished products. We leverageocean freight, which consumes lower amounts of fuel compared to air
freight, as our primary mode of transportation for inbound products, and wehave set a goal to ship 90% of inbound freight by ocean transport. However,in 2022, we fell short of this target due to a positive customer response to
the release of Omnipod 5. Shipping products by air freight allowed
customers to receive our life-altering products significantly faster. We willcontinue to pursue our ocean transport goal in 2023 as we align our efforts
to reduce emissions with our commitment to customer satisfaction.

At our corporate headquarters in Acton, Massachusetts, visitors can see avisible symbol of our commitment to sustainability—rooftop solar panels
installed as part of our multi-year solar project. This project generates
renewable energy to increase the sustainability of our local electricity gridand support the state of Massachusetts in meeting its renewable energy
goals. In 2022, we continued to implement the second phase of our solar
strategy and explore additional opportunities to invest in clean energy.
By leveraging renewable sources of energy, we support the acceleration,
development, and adoption of renewable technology.

We also optimize our shipments by shipping full pallets whenever possible toincrease efficiency and maximize the amount of product we can deliver. We
continuously pursue ways to reduce transportation emissions by shortening our
supply chain; for example, we source components locally, where possible, tominimize fuel consumption and increase the resilience of our network. For more
information, please see the Responsible Supply Chain Management section.

Energy Management
As our business grows, we work to reduce our GHG emissions by responsibly
managing our energy use and increasing operational energy efficiency—all while
continuing to drive the delivery of high-quality products. Additionally, we support
the adoption of renewable energy at our facilities and in our communities.

Last year, we also conducted a cross-functional renewable energy workshop
to educate our key stakeholders on various topics, such as renewable energy
market trends and drivers and the different types of renewable energy
instruments available in the markets in which Insulet operates. This
workshop helped to set a foundation of knowledge that will support Insulet’s
future GHG goal setting and carbon reduction work.

Many of the same trends that contributed to the increase in GHG emissions also
impacted our energy use in 2022. Due to expanded production capacity, employees
returning to in-office work, and the installation of a heated sidewalk to prevent slips
during hazardous weather, energy use at our facilities increased by 7% in 2022.

Our rapid growth and global expansion present unique
opportunities to implement sustainable and energyefficient processes as we develop new facilities to meetrising customer demands for Omnipod products. In June
2022, we began construction on a new manufacturing
facility in Johor Bahru, Malaysia. The plant will help tostimulate the region’s economy and create over 500
full-time jobs once the facility is operating at full capacity.
Insulet Malaysia strives to be the employer of choice andwill offer a progressive work environment, competitivecompensation, and outstanding job opportunities to local
candidates. We expect the manufacturing facility to be
operational in 2024 and to help us expand our production
capabilities globally to provide our customers with

Energy Consumption (MWh)[1]
Direct Energy Consumption

uninterrupted access to our products.

Indirect Energy Consumption

As part of our development, we are striving for both Green
14,026

12,824
8,279

10,065

Building Index (GBI) certification and Leadership in Energy
and Environmental Design (LEED) Silver certification at our
new plant in Malaysia. In alignment with these frameworks,

7,248

7,427

we are using a portion of materials with recycled content
to construct the building, and our designs incorporate
efficient technology for lighting, heating, and water

Energy Efficiency
Our Acton, Massachusetts manufacturing facility uses highly automatedprocesses that maximize product output, support energy efficiency, andreduce health and safety risks. We also work to ensure our buildings areoperating as efficiently as possible. For example, in 2022 we altered ourbuilding occupancy setpoints to consider the hours our employees spend
in the office, resulting in both energy and cost savings.

Groundbreaking Efforts in
Sustainable Manufacturingconsumption, including a rainwater harvesting system. We
also plan to install charging stations for electric vehicles.
Additionally, the facility will generate renewable energy
using rooftop solar panels to make the local electricity gridmore sustainable and resilient. Together, these measures
will optimize the facility’s energy use and enable us toresponsibly grow our manufacturing footprint.
2020

2021[2]

2022

[1] D
 irect energy consumption includes stationary and mobile fuel combusiton. Indirect energy
consumption includes purchased electricity.
[2] D ue to the acquisition of Insulet Irvine in 2022 and minor calculation methodology changes, thesevalues are a restatement of energy consumption as disclosed in the 2021 Sustainability Report.

22

Insulet 2022 Sustainability Report

Waste Management
We are focused on preventing waste generation and responsibly managing
waste disposal to benefit the local environment and the communities in which
we operate. We manage our waste footprint by understanding the mostimpactful sources of waste in our operations, adapting our processes to reduce
waste generation, and striving to divert any remaining waste away from landfill.

Assessment and Measurement
In 2022, we focused on leveraging the findings of our 2021 waste
characterization study to establish actionable process improvement plans toincrease our diversion rate from landfill. A qualified third party completed thiswaste study to understand the composition and drivers of our waste to enable
the creation of a thoughtful and data-informed waste diversion strategy. In late2022, we opened a new distribution center in Acton, Massachusetts, where webegan implementing improvements based on the findings of this waste study.
Our extensive planning process contributed to the strategic setup of optimized
waste infrastructure throughout our facility, including straightforward signage
and reduced use of waste-intensive items in breakrooms. We plan to continue
to implement similar changes across our operations over time, resulting inincremental improvement to our company-wide waste diversion from landfill.

Total Waste Diverted From Landfill
and Incineration in 2022 (Metric Tons)

We generate waste in our offices, laboratories, distribution center, andmanufacturing facilities. In 2022, we generated a total of 955 metric tons ofwaste, and we diverted 45% of our waste from landfill and incineration. Although
we generated more waste overall due to expanding operations and increasing
production volumes in 2022, including our acquisition of Insulet Irvine, ourdiversion rate increased. This was partly due to increased cardboard and plastic
recycling efforts in our Acton, Massachusetts manufacturing facility. Additionally,
we were able to harness unique opportunities to practice responsible waste
disposal. For example, when we moved out of our Billerica, Massachusetts
facilities, we recycled or repurposed as much office furniture as possible.

Manufacturing Waste
We promote operational consistency during the production process to
reduce the number of Pods that must be disposed of due to defects, nonworking parts, or other issues that do not meet our strict standards for
product integrity. In early 2022, we also began to expand our component
reclaim process for parts that must be disposed of during the manufacturing
process. If a partially assembled product contains defective parts, we reclaim
the remaining parts if they meet our quality standards for use in new Pods.
As we pursue these types of initiatives, we balance our efforts to minimize
our waste footprint with our commitment to the highest standards of quality.

Total Waste Generated (Metric Tons)
Waste Diverted from Landfill and Incineration

Waste Sent to Landfill or Incinerated

Percentage Diverted
45%
32%

45%
diverted

432
Waste Diverted from
Landfill and Incineration

46%
43%

523
Waste Sent to Landfill
or Incinerated

151

345
368

178

115

149

176

2021

2022

2021

Office/Lab/Distribution

283

2022

Manufacturing

Additionally, we reduce manufacturing and operational waste through ourBusiness Transformation programs. Several projects in our pipeline reduceenergy, manufacturing materials, or paper usage, and these improvements
in resource efficiency also offer associated cost benefits. Throughout 2022,
45 Lean and Six Sigma projects were ongoing, of which 44% were identified
as having a potential positive environmental impact. For information about
how we consider opportunities to minimize waste through thoughtful
product design and contribute to circular economy practices, please see theProduct Stewardship and Product Takeback sections; for more information
about our Business Transformation programs, please see the TalentManagement and Retention section.

Water Management
Although we do not use significant volumes of water in our operations,
we are committed to using water responsibly. We recognize that water
quality and scarcity are increasingly important problems, which may befurther exacerbated by climate-related impacts. As we grow and advanceour sustainability strategy, we continue to build a baseline for ourwater management approach to better understand our impacts on theenvironment and track our performance. In 2022, we used 1,162,812
cubic feet of water at our Acton, Massachusetts location.

23

Insulet 2022 Sustainability Report

Supplier Responsibility

Engaging our suppliers to ensure quality and responsibility as we growWe rely on our supplier network to support us in our
mission to deliver high-quality products that simplify
the lives of people with diabetes. In turn, we partnerwith our suppliers to align our supply chain with our
corporate responsibility efforts and quality requirements
as we grow to serve more customers around the world.
Leveraging industry relationships and resources, we
engage with our suppliers through our Supplier Codeof Conduct, audits, and trainings to enhance supply
chain resilience and uphold human rights.

Responsible Supply Chain Management
We expect our suppliers to conduct business with integrity, care for worker
wellbeing, and a commitment to environmental sustainability. In line withthis expectation, Insulet is a member of the Responsible Business Alliance(RBA), the world’s largest industry coalition dedicated to improving corporate
responsibility in global supply chains. We have adopted the RBA Code of
Conduct as our Supplier Code of Conduct, which serves as the backboneof our supplier responsibility program.
In 2022, we expanded supplier acknowledgment of our Supplier Code of
Conduct, conducted a social and environmental supply base risk assessment,collected and reviewed our first third-party RBA-aligned social andenvironmental supplier audit reports, maintained our strong supplier quality
practices, and leveraged our procurement strategies in new markets. As wemature our program, we continue to focus on resilience, risk management,
and quality.

Supplier Code of Conduct

Supplier Audits and Assessments

Our Supplier Code of Conduct guides our approach to responsible supply chain
management. We expect our suppliers to adhere to the standards set out in our
Supplier Code, which covers social, environmental, and business ethics topics.
The Supplier Code also references international norms and standards, including
the United Nations Universal Declaration of Human Rights, ILO International
Labor Standards, Organization for Economic Cooperation and Development(OECD) Guidelines for Multinational Enterprises, ISO standards, and many more.
The Supplier Code is an evolving document, updated every three years, thatincorporates stakeholder feedback and is available in over 25 languages.

While we maintain positive relationships with our suppliers and expect
compliance with our supplier responsibility standards, we also proactively
monitor potential risks to prevent negative impacts throughout our supply
chain. In 2022, we continued to build on our existing program by conducting
our first social and environmental supply base risk assessment using risk
data provided by the RBA. We used this data to prioritize requests forexisting RBA Validated Assessment Program (VAP) reports from our suppliers.
The RBA VAP sets standards for onsite environmental and social compliancecriteria and facilitates shareable audits conducted by independent firms. We
received and reviewed recent RBA VAP audit reports for 21% of in-scope,high-risk supplier facilities, and the Sustainability and Procurement teams areworking closely with relevant suppliers to address any identified issues.

We request our top-spend suppliers[1] to confirm that they have read andunderstand our Supplier Code, and in 2022, we increased the scope of thistop-spend definition to reach a wider base. In 2022, 96% of our top-spend
suppliers completed this task, and we engaged our suppliers to reach 100%
code acknowledgment for all 2022 applicable suppliers by early 2023.

Training and Capability Building
In 2022, we required all Insulet employees who regularly interact with
suppliers to complete Supplier Code training, and we achieved a 100%
completion rate. This included employees from various functions, including
Procurement, Supplier Quality, and Supplier Engineering. We also requested
our top-spend suppliers[1] to conduct the same RBA Code training required of
our employees. In 2022, 96% of our top-spend suppliers completed this task,
and we engaged our suppliers to reach 100% training for all 2022 applicablesuppliers by early 2023. We are proud to engage with our suppliers to build
their capacity to meet the standards of conduct required in our SupplierCode. Instead of simply mandating compliance, we work with our suppliers
as a partner, which strengthens our connections and encourages strong
environmental, social, and ethical outcomes.
[1] Defined as the top 90% (increased from 80% in 2021) of Pod bill of materials, value-added
manufacturing, and PDM supplier spend.

24

Insulet 2022 Sustainability Report

Furthermore, as we evaluate potential suppliers for our new manufacturing
facility in Malaysia, our Sustainability and Procurement teams arecollaborating to engage suppliers on how they prevent and mitigate potential
human rights risks, including risks related to forced labor in their recruitment
and employment practices. For more information about our new facility
under construction, please see the Sustainable Operations section.

Furthermore, we collaborate with our suppliers to understand the conflictminerals of tin, tantalum, tungsten, and gold (3TG) in our supply chain.
Insulet manages due diligence data and supply chain risks related to conflictminerals through our cross-functional 3TG Compliance Team, with oversightfrom our SVP of Global Operations. For more information, please see ourConflict Minerals Policy and most recent Conflict Minerals Report.

In addition to auditing responsible business practices, we perform supplierquality audits, maintain quality agreements with all suppliers, and provide
training to suppliers to promote their understanding of how their productinteracts with other Omnipod components. We perform systematic quality
audits against global quality management systems standards and regulations,
including but not limited to the ISO 13485 Medical devices – Quality
management systems standard every one to two years for our Class A
suppliers and every two to three years for Class B suppliers[1] to evaluate
regulatory compliance, quality, and responsible stewardship. In 2022, weenhanced our quality auditing processes for sub-tier suppliers. This
independent auditing process includes facility inspections to evaluate andtest quality control mechanisms, followed by assessments of Quality
Management Systems, controls and procedures, and product documentation.

Supply Chain Resilience[1] We classify suppliers in alignment with our risk management approach and consider multiple
factors, including if the supplier is single- or multi-sourced, what component the supplierprovides, and regulatory standards. Generally, Class A suppliers refer to contract manufacturers
and sterilizers, while Class B suppliers provide product components like plastics and metals.
Together, Classes A and B are our most key suppliers.

Recent years have proven how pandemics, natural disasters, and geopoliticalinstability can lead to supply chain vulnerabilities. At Insulet, we recognize
our responsibility to navigate disruptions because our customers could facecritical health risks without a continuous supply of our Pods. In 2022, we
continued to focus on addressing supply chain resiliency and efficiency as
we addressed lingering challenges from the COVID-19 pandemic. We strive
to always maintain on-time deliveries to our customers and implement
procedures to prepare for future disruptions.
Our supply chain resilience strategy integrates best practices that aim to
mitigate environmental and social impact. For example, we continue todevelop a regional supply chain network that allows us to move products
to customers faster in certain locations and avoid emissions associatedwith transportation. For our Acton, Massachusetts manufacturing facility,
we source the majority of Pod materials within 100 miles, and ourmanufacturing facilities in China use regional sourcing as well. Where
possible, we also incorporate dual and cross-qualified sourcing to maintainreliable access to high-quality components. In some cases, we must use solesourcing when component designs are proprietary, and we manage this riskby exploring engineering solutions and holding reserves in-house and at
supplier facilities to maintain continuity of supply.
We also aim to minimize supply chain risks by diversifying global operations
and establishing in-house manufacturing capabilities. In 2022, we secured
key manufacturing expertise by acquiring assets related to the design andmanufacturing of wire assemblies from one of our suppliers, Dynalloy, Inc.,
now referred to as Insulet Irvine. This strategic acquisition reinforces
operational efficiency, excellence, and resiliency by enhancing our ability tocontrol quality and logistics internally. For more information about ourbusiness continuity strategy, please see the Sustainability Strategy section.

In addition to enhancing supplier responsibility, we strive to minimize risks
related to security in our supply chain. We maintain certification through the
U.S. Customs and Border Protection’s Customs Trade Partnership Against
Terrorism program to identify and prevent potential threats.

Traceability
Maintaining the traceability of materials and products is critical to addressing
any potential quality concerns. We work closely with suppliers to establish
component and raw material traceability through our Quality Audit System,
which includes periodic audits of supplier product documentation systems
and traceability risks. In our operations, we maintain component-leveltraceability using part and lot numbering conveyed through text or barcodeson product labeling, and we report in compliance with global regulations,
including those mandated by the U.S. FDA and EU MDR, and align with ISO
standards. For information about our alignment with ISO standards, please
see the Product Quality and Safety section.
In our distribution chain, we utilize batch control processes for finishedproducts, and we generate regular batch reports to enable the traceabilityof all product batches by lot number. This process allows us to produce acomprehensive report containing full lot traceability to account for products
delivered directly to customers or distributors, as necessary. We expect
distributors to maintain similar traceability mechanisms.

25

Insulet 2022 Sustainability Report

Sustainable Product Innovation
We are revolutionizing diabetes management as a champion of innovation and customercentric designs that enable simplicity, freedom, and healthier lives. To expand upon our
mission, we strive to embed sustainability and inclusivity throughout our entire productlifecycle. Leveraging direct customer feedback and our expert research and design teams,
we continuously strive to build high-quality products that simplify people’s lives, accountfor resource consumption in our product and packaging designs, and explore the shift toa circular economy through our takeback programs. We remain committed to our quality
and safety standards throughout our comprehensive clinical trials and quality oversightprocesses. As we shape the future of diabetes management, we intend to further pioneer
customer-centric design, product sustainability, and circularity while maintaining strict
quality standards and driving positive impacts for all stakeholders.
In This Section
Product and Packaging Design
Product Takeback

Introduction

Our Approach to Sustainability

Resilient Operations

Sustainable Product Innovation

People and Communities

Appendix26

Insulet 2022 Sustainability Report

Product and Packaging Design
Innovating with customer centricity and the environment in mind
Simplifying the lives of people with diabetes is a corefocus throughout our innovation pipeline, quality
management system, and product design process. As
we evolve the next generation of diabetes management,
we invest in the strategic development of our products
and packaging to reflect the needs and interests of ourcustomers and support life-changing results.

Product Quality and Safety
Our dedication to product quality and safety represents the foundation of
our business and allows us to fulfill our purpose as a pioneering medical
device company. We maintain strict quality standards throughout the fullproduct lifecycle to uphold our responsibility to protect our customers whileadvancing our designs. Our management processes concentrate on
achieving full regulatory compliance, delivering safe and effective products,
and comprehensively addressing any potential shortcomings to maintaincustomer trust.
In 2022, our commitment to mitigating quality issues included taking quick
action to address complaints regarding the Omnipod DASH and Omnipod 5
hand-held devices. We announced two Medical Device Corrections in 2022:
one Class II correction for Omnipod 5 due to an issue with the Controller
charging port and cable, and one Class I correction for Omnipod DASH due
to PDM battery issues. We committed to providing replacements to allaffected Omnipod DASH customers and to Omnipod 5 customers uponrequest. Additionally, we increased investments in our customer support
capabilities, focusing on our call centers, to facilitate close and effective
customer communication.

Quality Oversight and Audits
Our product quality and safety governance procedures promote thehighest standards of quality during production and enable a thoroughresponse to any suspected discrepancy in quality. We monitor complianceand provide clear accountability and oversight throughout product design,
manufacturing, testing, procurement, and distribution. Guiding ourthoughtful approach, our Board of Directors receives regular updates on
Insulet’s quality and safety performance, policies, and initiatives. Our Vice
President, Quality Systems and Operations directly oversees our quality
management processes and reports to our SVP, Regulatory Affairs, Quality
Assurance, and Compliance, representing a shift in organizational structure
implemented in 2022 to enhance communication and efficient action related
to quality. Our senior leadership and multiple cross-functional working
groups receive monthly updates regarding product quality and safetymeasures to maintain oversight of any potential risks.
As Insulet expands globally, our Quality Management System (QMS)
promotes quality excellence throughout our operations while facilitating
continuous improvement and compliance with regional regulations. Our
owned and contracted manufacturing facilities that generate finishedmedical devices are all certified to the ISO 13485 standard, which outlines
specific QMS requirements for the medical device industry. A third party
conducts periodic facility audits to evaluate and confirm our continued
certification. We also maintain registration with the U.S. FDA, which
performs regular inspections of our QMS and our owned and contracted
manufacturing facilities.

Quality is at the core of everything we do to help
improve the lives of people with diabetes andenable our customers to enjoy simplicity,
freedom, and healthier lives through innovativetechnology—extending to the design of our
products, manufacturing, distribution, and the
support we provide to our customers. We
continually strive to apply the highest standards
and facilitate a positive experience with Omnipod.
LAETITIA COUSIN, SVP, REGULATORY AFFAIRS,QUALITY ASSURANCE AND COMPLIANCE

27

Insulet 2022 Sustainability Report

To monitor ongoing compliance, our Quality Operations department conducts
rigorous product testing and inspections at multiple stages of the manufacturing
process. This audit system employs both internal and external expert auditors
and is certified under the Medical Device Single Audit Program. Our Quality
Operations department also periodically audits our suppliers to confirm thatcomponents adhere to our robust quality standards. For more information
about supplier quality audits, please see the Supplier Responsibility section.
As we continue to enhance our quality management, we also streamline
processes where possible to increase efficiency and sustainability. For
example, Insulet previously used a significant amount of paper to print anddistribute QMS forms. To reduce resource consumption and modernize
recordkeeping in alignment with regulatory expectations, we are incrementallyshifting our processes to an electronic QMS (eQMS) platform. We facilitate thisongoing transition to electronic processes by providing employee training andclear communication about the changes. We look forward to standardizing oureQMS use as we establish our new manufacturing facility in Malaysia.

Quality and Safety Risk Management
Through our risk management program, we identify and respond to potential
issues and conduct regular risk assessments related to product quality andsafety. Our risk management process is aligned with ISO 14971, the medical
device industry risk management standard. Our Corrective and Preventive
Action (CAPA) program leverages the insights generated by our risk
assessments and informs how we identify, review, and correct any QMS or
manufacturing issues to prevent recurrence and customer impacts.
When products launch, we carefully monitor feedback from customers andhealthcare professionals so that we can take rapid action to address any
suspected quality or safety issues. We are proactive in any decision to launchfield action in response to complaints to protect customers and retain trust in
our business, and we continuously seek ways to improve the agility of ourcomplaint investigation and response. For example, we maintain a complaints
lab in Europe, which eliminates the need to send samples to the U.S. for testing
and complaint investigation. Our facilities in the region can more quickly
evaluate local quality concerns while reducing the environmental and financial
resources needed to transport materials overseas. Additionally, we evaluate
emerging regulations during our research and design phase to proactively
account for compliance with future product quality and safety standards.

Alignment With Global Leading StandardszISO 13485: Effective Quality Management System in the medical
device industryzISO 14971: Risk management for the medical device industryz

I SO 11607-1 and ISO 11607-2: Packaging for terminallysterilized medical deviceszISO 11135: Sterilization of healthcare productszISO 10993: Biological evaluation of medical devices

Employee Education and Training
Product quality and safety rely on an expert workforce that is vigilant, proactive,and dedicated to our customer-centric mission. All employees must complete
quality and regulatory compliance training during new hire orientation, and we
provide additional training based on employees’ roles and responsibilities. For
example, our Manufacturing, Quality, and Regulatory teams complete additional
training on Lean Principles and 8D problem-solving techniques. Thesefundamentals, which are integrated into our QMS, empower employees toimprove process capability, reduce waste, and mitigate product defects.

Ethical Clinical Research
Clinical research and field studies carefully measure outcomes to confirm
that our products are safe, as well as produce the intended improvements inquality of life. Our SVP and Medical Director manages our robust standards
for ethical conduct and research subject safety and wellbeing, and an
Independent Review Board oversees our clinical trials to monitor compliancewith relevant laws and regulations. We align with Good Clinical Practice,a recognized standard for ethics and scientific quality, to protect privacy
rights and data integrity. We do not allow or outsource animal testing.

We maintain dialogue with regulatory bodies throughout the trial design
process to discuss safety, and the U.S. FDA reviews and approves significant
risk protocols before we begin testing. When data are available following trial
conclusion, we publish our findings in peer-reviewed scientific journals andengage with industry experts at conferences.

Responsible Sterilization and Packaging
Our Quality Engineering team manages the sterilization of all products
conducted by third-party partners. Our processes and partners adhere to
global quality management system requirements and ISO 11135 standards forthe development, validation, and routine control of sterilization processes for
medical devices. Ethylene oxide is a standard sterilant in the healthcare andmedical device industry. However, the compound is designated as a hazardous
air pollutant by the U.S. Environmental Protection Agency (EPA), which
mandates vigilant health and environmental controls in the interest of ouremployees, business partners, and customers. Our distribution centers employ
robust ethylene oxide residuals testing procedures, and we collaborate with
our partners to reduce the usage of this chemical where possible.
In 2022, we continued to collaborate with our sterilization partners to validate
advanced equipment that uses filler gases to reduce the ethylene oxide
concentration required while maintaining levels needed to eliminate
contaminants and uphold product sterility and safety. In 2023, we plan tocomplete the validation of this optimization at several global sites. Additionally,
we are exploring the feasibility of long-term alternative sterilization methods.
Managed by our Quality department, our strict packaging quality standards
prevent contamination and tampering during delivery to customers. Our
packaging meets international standards, including ISO 11607-1 and ISO
11607-2 for packaging for terminally sterilized medical devices, ISO 11135 to
inform sterilization of healthcare products, and ISO 10993 for the biologicalevaluation of medical devices. For more information about our process toimprove the quality and sustainability of our packaging, please see theProduct Stewardship section.

28

Insulet 2022 Sustainability Report

Customer Centricity
We pursue each opportunity for innovation with the goal of improving ourcustomers’ lives. Customer satisfaction is a top priority, and we leverage ourcustomer relationships to hear directly from the diabetes community about
their expectations and challenges so that we can understand how to maketheir lives simpler and easier. We continue to advance our products byincorporating new features, such as CGM and smartphone integration.

Customer-Focused Design
Our hardware and software teams orient our design efforts around the wide
range of unmet needs of the diabetes community, accounting for diversity inlifestyle and personal preferences. Some of our customers are parents toyoung children with diabetes; others are athletes who need durable andwaterproof products. We aim to simplify diabetes management for all typesof customer needs. Our Pods can be worn for up to three days at a time andare tubeless and waterproof. Additionally, the Pods can deliver insulin
continuously and eliminate the need for daily injections, so customers canenjoy greater flexibility when performing daily activities.

These innovations are not possible without customer feedback regarding
firsthand experiences with our Pods, and we believe that customer
engagement during product development is vital to improve outcomes. We
meet with customers, consult with advocacy organizations, and conduct user
experience research to closely understand potential improvements andsolutions available to people living with diabetes. In 2022, we participated in
the MedTech Patient Engagement Think Tank to develop a framework forcustomer engagement throughout the product lifecycle—from research anddevelopment to commercialization. By capturing and incorporating customer
experiences and priorities during product development, we can better serve
customer needs, increase access to our products, and improve healthoutcomes. We gain additional customer insight during human factor anduser experience testing of our products in development.
In pursuit of our mission, we also build inclusivity into the products
themselves. Customers in the U.S. can use the Omnipod DASH PDM in both
English and Spanish, and in 2022, we continued to develop marketing
materials, training information, and the Controller to support the Omnipod 5
user experience in Spanish. We remain dedicated to listening to ourstakeholders to identify additional ways to make our products more inclusive
and serve the diverse diabetes community.

Quality andCompliance Week
Every year, our global workforce joins together to learn,reconnect, and engage during Quality and ComplianceWeek. In 2022, we celebrated the renewed ability tocollaborate as a team through the theme of “Reconnecting
Around the World.” Centered around in-person activities at
our Acton, Massachusetts headquarters, the week included
presentations from executive leadership, discussions led
by external experts, and two panels where our customers
shared how Omnipod simplifies their lives. Quality andCompliance Week continues to emphasize our culture ofquality and energize our employees as they work to deliveron our purpose.

9

guest speakers>7,000training hours

80

sessions

600

56

presentersin-person participants

29

Insulet 2022 Sustainability Report

Care, Inc.’s CGMs with Omnipod 5. As we build the next generations ofOmnipod, we are committed to continuing to leverage technologicaladvancements while maintaining our focus on data privacy and productsecurity. For detailed information on how we manage risks associated with
our technology, please see the Data Privacy and Cybersecurity section.

Christian’s Story
Parents Liz and Kevin know first-hand what it’s like to have

Similarly, Omnipod DASH and Omnipod 5 incorporate innovative technology,
including a secure Bluetooth®-enabled Pod and PDM/Controller, whichenables users in the U.S. to automatically upload data to the cloud, providing
users and their clinicians with critical insights.

a child with type 1 diabetes. Their 6-year-old son, Christian,
was diagnosed with type 1 diabetes at just 3 years old.
Christian loves swimming, hoverboarding, and playing withhis three sisters, so Liz and Kevin knew that neither tubed

Customer Training
Omnipod offers an easy-to-use system that reduces the training burden on
healthcare professionals and end users. However, diabetes management
can still be complex, so we provide Omnipod training materials that arecomprehensive and accessible to promote successful health outcomes andcustomer retention. We have streamlined and standardized our onboarding andtraining by developing improved online resources such as training videos, online
user guides, and Pod University™—a one-stop source for interactive educationalguides that help people with diabetes, caregivers, and educators learn about thebasics of living with diabetes and the science of diabetes management. Eachguide is also available in Spanish and accessible on mobile devices.

Smarter Technology
Our product design process incorporates technology advancements thatenable our customers to seamlessly integrate diabetes management into
their everyday lives. Our customers have communicated that they want theoption to use their personal smartphones for diabetes management. Basedon this feedback, we designed Omnipod 5 so users can monitor and control
their glucose levels and insulin dosing through a secure mobile app on theircompatible smartphones in addition to our Controllers. The application iscompatible with Android devices, and we are currently working on iOS
compatibility so users with an iPhone can control Omnipod 5 Pods. With
SmartAdjustTM technology, the Omnipod 5 App and Dexcom G6 CGM are in
constant wireless communication, enabling automatic adjustments to insulindelivery that offer users new levels of freedom. In addition, we have adevelopment and commercialization agreement to integrate Abbott Diabetes

pumps nor multiple daily injections were going to work fortheir active son. They love that their family gets the bestof both worlds with Omnipod® 5—they get the peace ofmind they want from an AID system, and Christian doesn’t
miss a beat when it comes to being a kid with the tubeless,waterproof Pod.

Additionally, we have increased the size of our Field Clinician team to directlytrain new users and have continued to utilize our virtual training programs,
which allow users to onboard in a comfortable environment and withmultiple family members present. For more information on the support andresources we provide to our customers, please see the Omnipod website.

Customer Satisfaction
We always strive to exceed customer expectations, provide high-quality
customer support, address any product issues rapidly and comprehensively,
and instill trust in Insulet’s mission. Our Consumer Marketing and User
Experience teams gather customer feedback through regular customer
surveys, call centers, and extensive research. We integrate industry insights
and consumer input from multiple stakeholders, including healthcare
providers, payors, advocacy organizations, and retailers, to create productsthat produce positive health outcomes and reflect our credibility.

Watch Christian’s Story here30

Insulet 2022 Sustainability ReportInnovation, Research andDevelopment, and Intellectual Property
Effective research and development harness the power of our expert
workforce, who continue to deliver revolutionary products that simplify the
lives of people with diabetes. Our Research and Development teams
collaborate to constantly evaluate innovative solutions, incorporate advanced
algorithms, enhance digital integration, and reduce resource use during thedesign phase.

We follow a formalized technology and product development process thataligns with best practices and global quality system regulations:Stage 1: Product Definition
Commercial and clinical teams identify unmet user needs or opportunities tooffer product solutions that significantly enhance the user experience.

Stage 2: Early-Stage Feasibility
Teams conduct in-depth research and feasibility studies to start broadly
solving the core problem(s) and any peripheral problems in the space.
z enerate, prototype, and test concepts to provide confidence in theGsolution spacezCreate and file intellectual propertyz onduct early user validation activities to ensure the product addressesCcore customer requirements and unmet needszEstablish business cases and achieve organizational alignment

Stage 3: Design Controls
Insulet has robust design control processes which adhere to quality systemstandards and regulations and range in duration depending upon thecomplexity of the program and product.
zPhase A: Concept and Initial PlanningzPhase B: Design Planning and InputzPhase C: Design and Development/OutputzPhase D: Design Verification and Validationz

Phase E: Design TransferzPhase F: Release to Market and Post-Market Surveillance

Product StewardshipWe strive to meet stakeholder demand for more sustainable products by
evaluating opportunities to reduce the environmental impact of our products
when sourcing materials, designing devices, and manufacturing products andpackaging. The strict regulations in the medical device industry introduce
unique challenges, but our research and design teams consistently develop
innovative ways to reduce resource use at every stage of the product lifecycle
without compromising on our quality and safety commitment.

Conscious Design and Production
Our design teams welcome the creative challenge of evolving our Pods to improvematerial use efficiency and recyclability while maintaining strict adherence toquality and safety standards. From the initial concept ideation phase, our teams
consider designs that integrate more sustainable materials and promote
reductions in landfill waste. In 2022, we focused on optimizing the design of the
top and bottom housing components of our Pods to reduce plastic waste
generated during manufacturing. We expect these changes to increase
operational efficiency and enable us to decrease plastic consumption.
Additionally, we are exploring opportunities to integrate alternatives to virginplastic into our Pod design. In general, our conscious design efforts explore how
to make our devices more resource-efficient, incorporate renewable materials,
and make disassembly easier for streamlined recycling. Our Controllers and many
PDMs already use rechargeable batteries, and Pod batteries do not contain heavy
metals such as mercury. Our devices avoid hazardous materials in compliancewith the EU Restriction of Hazardous Substances (RoHS) requirements.

31

Insulet 2022 Sustainability Report

Our Packaging Redesign Process

Reviewed product sustainability
guidelines and stakeholder input

In 2022, our cross-functional Packaging and Labeling working group
continued to explore opportunities to design more user-friendly andenvironmentally sustainable packaging. The group leverages customer
feedback to review new and existing designs, evaluating ease of use andsustainability. In 2022, we redesigned our U.S. Omnipod 5 starter kit
packaging, making the boxes, sleeve, and internal tray 100% recyclable, andwe reduced the total packaging volume by over 60%. Additionally, we
digitized our roughly 400-page user guide, which is provided to every new
customer, contributing to an estimated savings of 100 metric tons of paper
per year. We plan to execute these changes in our starter kits in 2023. In
total, we estimate that our packaging redesign and digitalization efforts will
reduce the GHG emissions of our starter kit packaging by 77%.[1]Identified gaps in recyclability andease of use

We are also taking steps to reduce waste in our manufacturing andprocurement processes. For example, we recirculate trays that suppliers use
to ship components to our manufacturing facilities. For more information
about our efforts to mitigate waste generated in our operations, please see
the Waste Management section.

Developed cross-functional Packaging
and Labeling working group

Circular Economy
Evaluated digitizing user guides andredesigned starter kit packaging

Implemented single-stream
recyclable cardboard packaging andcompleted user guide digitalization

Reduced packaging volume byover 60%

Global businesses are increasingly receiving stakeholder feedback to taketargeted steps to shift toward a circular economy, which reevaluates thedominant model of production and consumption to reduce waste, extend a
product’s useful life, optimize product design, materials, and services, andmaximize reuse potential and product value. As we grow and mature ouroperations, we see opportunity to improve materials and process efficiency,
reduce resource consumption, and build business resiliency through circular
economy initiatives. A circular business model would allow for the raw
materials in the Pod, PDM, and Controller to be reused, recycled, or
repurposed. Waste reuse and repurposing remains a challenge in the
medical device industry due to strict regulations for handling biohazardous
waste and the disposable nature of many products, so we are exploring
solutions related to minimizing resource use, leveraging recyclable andrenewable materials, and investigating safe reclamation of ourmanufacturing waste. These initiatives can provide financial as well as
environmental benefits by improving efficiencies and reducing the cost ofsourcing virgin materials and transporting waste to landfills.
[1] This emissions reduction is calculated with respect to ISO 14067 guidelines.

100

metric tons of paper
saved each year due touser guide digitalization

100%
recyclable cardboard
packaging components for
the Omnipod 5 starter kit

77%

estimated reduction in GHG
emissions from Omnipod 5
starter kit packaging redesign

32Insulet 2022 Sustainability Report

Product Takeback

5,809,468

Harnessing the full value of our products to advance a circular economy

Pods accepted for takeback in 2022
By reclaiming and recycling or reusing product raw
materials, we can continue to extract value from our
product materials, thereby extending their useful life.
We are facilitating responsible disposal of our products
through our product takeback programs, which enable
impactful waste management for our customers andcontribute to the circular economy. We continue toadhere to applicable requirements to properly disposeof medical waste while operating our takeback programs.

Takeback Programs
The purpose of our takeback programs is to facilitate a circular approach
to waste and to allow our products to add value beyond customer use.
Customers are increasingly interested in reducing their individual waste
footprint, which is why we strive to make Pod takeback easy and effective.
In 2022, we continued our established Pod takeback programs in Europe
and Canada and implemented a new program in Australia. Through our
takeback programs, customers can return their used Pods for responsible
disposal. Furthermore, we introduced a product takeback pilot in
Massachusetts to explore a U.S. product takeback model and gain a better
understanding of how to enable these measures at scale throughout thecountry. We look forward to evolving product takeback options as Insulet
grows and considers novel recycling or material reuse processes based on
local regulations and available services.

These programs extend the use of Pod materials through multiple avenues.
In certain countries where we implement a takeback program, such as
Canada, Germany, and the U.K., customers receive return packaging witheach product shipment to facilitate easy mail-in collection of used Pods. In
France, customers can drop off used Pods at select pharmacies in a return
carton. Through our takeback program in France, 95% of Pod materials by
weight are recycled. Once these Pods are collected, they are disassembled
into metallic and non-metallic parts, and an automated robot separates thebatteries from other electrical components for recycling. The Pods areprocessed through a shredding machine, and non-metallic ore materials arefurther separated into stainless steel, lead, copper, gold, plastic, and fiber, allof which are sent to specialized channels for recycling. Throughout most ofEurope and in Canada, reclaimed Pods are incinerated to generate electricity
at waste-to-energy facilities.

Product Takeback (Metric Tons)
Total weight of Pod materials accepted for takeback
150.0
135.8

39.0
22.0

2019

2020

2021

2022

33

Insulet 2022 Sustainability Report

People and Communities
Improving the lives of people with diabetes is central to our mission at Insulet. As wecontinue to enable transformative health outcomes through our products, we also lookbeyond treatment to uplift lives by reducing health barriers and disparities, improving
community health, fueling innovation, and advancing the next generation of healthcaretechnology workers. We partner with organizations, both local and global, to advancethe wellbeing of our customers and facilitate access to critical products for diabetes
management, and we are championing advocacy as we serve as leaders in the diabetes
community. We also contribute to holistic wellness among our own employees by building
an inclusive and inspiring culture that enables career growth and empowerment. We
continue to develop our own workforce, foster a respectful, safe, and engaging environment
for our teams, and provide opportunities to become involved in the communities we serve.
In This Section
Health and Wellbeing
Attracting, Engaging, and Developing Our Talent

Introduction

Our Approach to Sustainability

Resilient Operations

Sustainable Product Innovation

People and Communities

Appendix34

Insulet 2022 Sustainability Report

Health and Wellbeing

Improving lives of people in the global diabetes community
Our dedication to our customers extends beyond
product development; we believe that everyone in the
diabetes community should have equitable access tothe highest possible quality of life. We strive to shape
the healthcare, business, and policy environment tosupport the needs of our customers and encourage
the adoption of innovative technology, and we apply
this mindset to our strategic approach to new markets.

Value, Affordability, and Accessibility
We strive to reduce access barriers and maximize the value of our products
for people with diabetes worldwide. Restrictions on coverage that impact
accessibility persist in many countries, irrespective of healthcare systemdesign, and our teams continuously develop innovative solutions to enable
greater access to the value our products provide. We also collaborate withgovernment agencies and other payor organizations to reduce accessbarriers by considering local conditions that may affect cost of care, user
experience, and outcomes. We seek to enable everyone with diabetes
to live their healthiest lives by advancing HealthTech for all, expanding theaccessibility of Pod therapy, and reducing health disparities.

Access to Better OutcomesWe believe, as supported by emerging research, that investing in access to
medical device technology significantly improves long-term health outcomes
and reduces the total cost of care. Studies suggest that the use of Omnipod
by individuals with either type 1 and insulin-intensive type 2 diabetes acrossall age groups is associated with better glycemic control and reduced
frequency and severity of hypoglycemic episodes. Our 2017 Omnipod claims
data also demonstrated significant reductions in emergency department
visits and hospitalizations. We have and will continue to gather additional
data regarding Omnipod DASH and Omnipod 5 outcomes in 2023. Our
products continue to enhance individual lives and create value for entire
healthcare systems.
Additionally, Insulet’s Value and Access team studies how our onboardingand education processes allow customers to adapt more quickly to our
products compared to MDI therapy or the use of traditional tubed pumps.[1]Omnipod allows customers to simplify their lives through a streamlined
process and offers a positive customer experience supported by our
dedicated team. We believe that the impacts of these benefits reverberate
throughout families, communities, and health systems.
[1] Jennings P, Hopley C, Lauand F, Littlewood M. (2022) Care Efficiencies with Tubeless Vs Tubed
Pumps: A Time-and-Motion Study of New Insulin Pumps Users. [Poster presentation]
Association of British Clinical Diabetologists Conference 2022, Birmingham, United Kingdom.
https://abcd.care/resource/poster-18-uk-time-and-motion-study-initiating-tubeless-and-tubeinsulin-pumps

Promoting Inclusivity
for People with Diabetes[1]In 2022, Insulet created an activation to celebrate diversity
and inclusivity for people with diabetes in the popular
Nintendo® video game Animal Crossing™: New Horizons.
We developed custom outfits that allowed people to show
off their diabetes with pride, including insulin pumps andaccessory bags. The program also featured Omnipod
Bay, a diabetes-themed island containing adventures andexperiences such as booths for advocacy organizations,
including JDRF, Beyond Type 1, Children with Diabetes,
and the Kyler Cares Foundation. This unique program wasdesigned to address the limited representation of people
with diabetes in gaming and popular culture and normalize
the use of diabetes management accessories.
[1] Insulet Corporation is not affiliated, endorsed, or otherwise associatedwith Nintendo Co., Ltd., Nintendo of America, Inc. or any of theirsubsidiaries or affiliates. The names Animal Crossing™: New Horizons,Nintendo® and Nintendo Switch™, and their related marks and logos
are trademarks or registered trademarks of their respective owners.

35

Insulet 2022 Sustainability Report

Our approach to accessibility considers how we can reach underserved
populations, such as people with type 2 diabetes, to deliver better outcomesthrough our technology. Insulet estimates that, out of our worldwide total
addressable market of approximately 11 million people, approximately 55%
have insulin-intensive type 2 diabetes. By increasing access to our products
for people with type 2 diabetes, we have the potential to reduce thefrequency of emergency room visits, hospitalizations, and other major healthdisruptions. Through our customer-centric innovation pipeline, we are also
working to address the specific needs of customers with type 2 diabetes bydeveloping a basal-only pod that could serve over three million people in the
U.S. This product would allow us to serve a greater number of customers andsimplify their diabetes management.
We also explore opportunities to improve accessibility and inclusivity. In
2022, we continued our ongoing effort to develop Omnipod 5 training andmarketing materials in Spanish. For more information about how we develop
products to enhance the customer experience, please see the Customer
Centricity section.

Pricing and Distribution
We aim to enhance affordability and accessibility when engaging payor
organizations, developing pricing models, and designing product distribution
strategies. Where possible, we employ a pay-as-you-go business model thatremoves barriers to access by decreasing up-front hardware costs. This also
allows customers to experiment with their care regimen since there is nocost associated with changing product types, as opposed to traditional
insulin pumps, which often require customers to pay a significant upfront
cost, commit to a four-year lock-in period, and pay a fee to switch products.
The pay-as-you-go payment option is available to customers in the U.S. andother select countries, and we are exploring opportunities to launch thismodel in additional markets. We also offer a 10-day free trial for Omnipod 5.

Approach to New Markets

To further promote flexibility, we also offer free demo Pod Experience Kits
and Omnipod DASH trials, ranging from 30- to 90-days, based on the market.
Additionally, we provide a Financial Assistance Program in the U.S. to help
eligible customers continue to enjoy the benefits of Omnipod when financial
challenges arise. Customers who are uninsured, have insurance that does
not cover Omnipod or one of its individual components, or cannot afford
their out-of-pocket insurance obligations may apply for this program.
Furthermore, we offer a copay card program through the pharmacy channel
to lower the total out-of-pocket costs for qualifying customers. In 2022, copay
cards reduced the average copay costs by $5 per month for Omnipod 5 andOmnipod DASH users, for an average copay of less than $50 per month after
one year.

We estimate that approximately 40% of the type 1 diabetes population in the U.S.
and even less of the type 1 diabetes population internationally use insulin pumptherapy.[1] An even smaller portion of the global insulin-intensive type 2 diabetes
population uses insulin pump therapy. We believe these factors generatesignificant opportunities to expand our breadth of impact as we enter global
markets and differentiate our products. We launched Omnipod in Saudi Arabia in
April 2022 and the United Arab Emirates in May 2022. In Middle Eastern markets,
we leverage a unique hybrid business model, where a cross-functional teamengages with our local channel partners regarding reimbursement, onboarding,
medical education, regulatory affairs, and marketing, which allows us tounderstand evolving customer needs and connect to our end users more closely.

In the U.S. market, Omnipod 5 and Omnipod DASH are available in major
retail, mail-order, and specialty pharmacies. As pharmacists continue to playa larger role in customer care due to convenience or preference, it is criticalto make our product available through the pharmacy channel to enhanceease of access and further differentiate our products. The majority of
Omnipod 5 and Omnipod DASH users pay a monthly copay less than $50
USD per month in the U.S., with many paying nothing. We have also
eliminated lock-in periods for our products distributed through pharmacies,
increasing flexibility and the ability for customers to control their productselection. We are committed to continuing to work to expand the breadth ofaccess across the retail pharmacy market.

As we expand into additional international markets, we carefully consider bestpractices to maximize value and accessibility in each country’s unique regulatory
and economic environment. Our International Market Access team develops
payment structures, creates roadmaps to accelerate product adoption, andengages with local stakeholders to advocate for a positive policy landscape in newmarkets. We also established an International Market Access Center of Excellence
housing health economic and outcomes research, policy, public affairs, andpricing specialists who support evidence-based tools and value narratives for Pod
therapy. We are currently developing our international strategy for interactingwith regulators and payors in new markets, with goals of increasing diabetes
understanding and education, efficiently meeting the demand for our products,
and fostering equitable access to diabetes management.
[1] Insulet, 2022 Form 10-K.

36

Insulet 2022 Sustainability Report

Policy and Advocacy

Strategic Partnerships

As we increase our impact within the global diabetes community, we havemade great strides to mature as a leader in public policy and advocacy.
Working alongside trade associations and advocacy organizations, we use
our influence to take an active role in shaping the policies that affect our
stakeholders, specifically regarding technological innovation andhealthcare accessibility. Diabetes technology is rapidly advancing, and wework to make sure policies are in place to support acceleration to market
with a continued focus on outcomes and equity. Regular dialogue withcustomers, physicians, investors, and business partners enables us topromote a common understanding of diabetes and accurately characterize
our stakeholders’ needs.

Our partnerships and sponsorships with industry and consumer advocacy
groups are essential to enhancing awareness, supporting affordability andaccessibility, improving health outcomes, and advancing innovative research.
In 2022, we partnered with a variety of advocacy groups while making astrong effort to pursue active leadership roles to increase our impacts.
Examples of our partners include:

Government Affairs
Our advocacy efforts continue to evolve in response to the dynamic
regulatory environment and in alignment with our rapid business growth. In
2022, our Government Affairs team enhanced our engagement strategy,
which improved our ability to identify and leverage the most impactful policy
opportunities. Our experienced Government Affairs leadership also
dedicated more time to building strong relationships with our regulatory andlegislative stakeholders. Looking ahead to 2023, our international teams areembarking on a public affairs strategy to influence and shape policy acrossmultiple markets with the shared goal of improving the lives of people withdiabetes through access to effective diabetes technology, such as Pod
therapy. In pursuit of the continuous improvement of our advocacy efforts,
we periodically benchmark our global program to assess unmet needs andidentify opportunities for further leadership in advocacy.

z ssociation of Diabetes Care & Education Specialists (ADCES): ThisA
organization is comprised of more than 14,000 diabetes and education
care specialists dedicated to improving diabetes care. Insulet is amember of its Industry Advisory Board and has collaborated with ADCES
to provide innovative educational programming and support policies
that ultimately improve the lives of people living with diabetes.

z

JDRF: This leading global organization is harnessing the power of
research, advocacy, and community engagement to advance lifechanging breakthroughs for people with type 1 diabetes. We support
JDRF in all of their active markets, which includes the U.S., Australia,
the Netherlands, Canada, the U.K., and Israel.

z hildren with Diabetes: Children with Diabetes is an organization
C
dedicated to providing education and support for those families livingwith type 1 diabetes.

z ational Federation for the Blind: This organization advocates forN
the rights and inclusion of blind and visually impaired people in the
U.S. In 2022, Insulet collaborated with this organization to advanceunderstanding of the needs of people who have visual impairments
related to diabetes.

37

Insulet 2022 Sustainability Report

Attracting, Engaging, and Developing Our Talent
Cultivating an energizing, high-performance, and engaging culture while taking action to support our local communities
In 2022, our people raised the bar for excellence as they
delivered Omnipod 5 to market in the U.S. and navigatedsignificant growth amid a continuously evolving global
working environment. The impact that Insulet made on
the diabetes community in 2022 is a direct reflection of
our employees’ perseverance, our culture of innovation,and our strong talent management strategy. We strive
to be the employer of choice, and the key to our successis our commitment to proactively adapt and evolve ourtalent programs to keep pace with our rapidly expandingorganization and external market dynamics. We facilitate
the growth and success of our employees througheffective talent attraction and development, competitive
benefits, a values-driven diversity and inclusion strategy,a safe working environment, and ample opportunities
to give back to our communities.

Talent Management and Retention
Our team of over 4,500 employees and contractors contribute to our growththrough expert health technology innovation, business acumen, and creative
inspiration to achieve the remarkable and serve our customers. Our people are
critical to our success. As such, we provide a differentiated focus on attracting,managing, and developing medical technology skills and leadership. At Insulet,
our talent management approach involves creating a great employee
experience that engages our talent and differentiates us in the market.

Our efforts build upon our foundational culture of inclusivity and belonging,where employees are empowered and their ideas are welcomed, enablingthem to bring their best selves to work every day.

Talent Attraction
At Insulet, we are working to develop the next generation of the HealthTech
workforce, driven by the purpose of making life simpler for the diabetes
community. We are a dynamic and rapidly growing organization, and we believethat this presents a uniquely valuable opportunity for skilled candidates to shape
our future. We conduct outreach with university students and promote interestin the Company through our cooperative education (co-op) program, locatedprimarily in our manufacturing and research and development functions, which
offer hands-on work experience, technical and professional skills development,
and education in the medical device industry. In 2022, we hosted over 120
students through our internship and co-op programs.
Furthermore, in 2022, we prepared the groundwork for collaboration witha technical school near our Acton, Massachusetts headquarters to establish
a medical technology manufacturing curriculum, fund enrollment forinterested students through government support and Insulet contributions,and hire these students upon graduation. This partnership will commence in2023 and is possible because of the Massachusetts RENEW program, whichhelps companies establish sustainable talent development pipelines to build
highly skilled and diverse workforces.
In addition to our successful early-career talent attraction efforts, we strive
to attract skilled and experienced talent representing a variety of careerlevels. Our Future of Work program, which allows for flexible working
arrangements, has enabled us to reach a diverse group of talent that waspreviously restricted by geography.

We also have a responsibility to the communities we serve to mitigate the risk ofbias during our talent acquisition activities. Building a workforce with a diversityof identities and experiences helps us innovate to better serve our stakeholders.
For more information, please see the Diversity, Equity, and Inclusion section.

Talent Management and Professional Development
Our sustainable growth and reliable product delivery depend on our ability toretain our workforce and maintain a strong internal talent pipeline. In 2022,
we established consistent global talent practices and tools and continued toenhance them to protect our most valuable asset: our employees. Additionally,
we deepened our succession and talent pipeline planning for our Executive
Leadership Team positions, our Enterprise Critical Roles, and multiple levels of
positions within our Operations organization. We continue to facilitate targeted
professional development opportunities for those identified as potential
successors. In 2023, we plan to further broaden this work by creating
succession and pipeline plans across all functions.

4,706

total employees and contractors in 2022, which
represents a 35% increase from 3,474 personnel
in 2021[1][1] Employee data includes permanent and temporary workers. Data reflects our
employees as of December 31, 2022.

38

Insulet 2022 Sustainability Report

In addition to our targeted talent management practices, we remain committed
to fostering an environment of continuous learning and development acrossour entire employee population. As part of this focus, in 2022, we hired a
Global Head of Leadership Development and Learning within our Talent andOrganizational Development Center of Excellence. This position provides
dedicated leadership focused on expanding our work to grow and develop ourtalent for the future. In 2022, we continued to deepen our career development
and professional development programs through the following initiatives:z areer Development Planning: In 2022, we expanded our offeringsCand launched our first flagship Career Development Program, “IgniteYour Growth,” to employees across the globe, building their capability tocreate robust career development plans for their future at Insulet. Over2,000 employees participated in the program in 2022, and our employee
engagement surveys demonstrated excellent satisfaction with theprogram. This live, interactive program, offered in multiple languages,
brought colleagues together from around the world to share their career
experiences, grow in their self-awareness, and identify actions tomaximize their growth and impact. Over 80% of participants went on tohave career development conversations with their managers and createcustomized career development plans for their future. This work willcontinue in 2023 and beyond for employees who join our Company.

zPerformance Management: Integrated into our operational planningand compensation process, our performance management process
defines opportunities for managers to foster dialogue with their teams,
provide feedback, and identify areas where additional development can
optimize performance. All employees participate in our performance
management process.

z

 .I.T.E. (Respect, Integrity, Teamwork, Excellence) Start New HireR
Education: Our global R.I.T.E. Start onboarding program introduces new
employees to our core values and educates them about diabetes and ourOmnipod products, business strategy, culture, and mission. In 2023, weplan to continue to make our onboarding process more consistent andimpactful for global employees as we expand our operations. We alsooffer intensive Customer Care New Hire training and Sales (Field andInside Sales) New Hire training to quickly upskill our new employees inthese areas.

zzI nsulet Learning Platform: We currently utilize an on-demand
Insulet learning platform in partnership with a third party. Based onneuroscience principles, this microlearning program delivers digestible
content that promotes opportunities to improve mindfulness, innovation,
inclusion, and other priorities. In 2023, we plan to expand this offering sothat every Insulet employee will have access to online learning materials,
which offer continued education to any interested employee.

zUpskilling Program: We continue to sponsor a two-year workforce
training program to upskill our manufacturing employees who work in
Massachusetts. Recently promoted supervisors and other interested
candidates participate in trainings that cover topics such as effective
problem-solving techniques, supply chain management, conflict
resolution, team building, Lean and Six Sigma, and Define, Measure,
Analyze, Improve, and Control (DMAIC) principles.

z usiness Transformation: To upskill employees, maximizeBperformance, and minimize waste, our Business Transformation
program supports Lean and Six Sigma training and related employee
projects across the Company. In 2022, we offered five waves of Lean
Green Belt training for interested candidates to lead continuous
improvement projects. In addition, we offered Lean Champion Training
to Finance, Quality Assurance, and Regulatory and Complianceemployees, and we provided two rounds of Six Sigma training.

zTuition Reimbursement: As part of our comprehensive benefits
program, we provide professional certification course reimbursementof up to $3,000 annually. We also offer tuition reimbursement of up
to $5,250 annually for courses taken in pursuit of an undergraduate
degree and up to $10,000 annually for courses that contribute to a
graduate degree in support of formal professional development andlifelong learning.

 ew Manager, Leadership, and Technical Training Programs: First-lineNmanager training, skills workshops, and leadership development initiatives
enhance the capabilities of our employees to improve their performancein current positions and to prepare them for future positions.

39

Insulet 2022 Sustainability Report

Our Culture Evolution

Conscious Talent
Development for
Software Excellence
Our Software for Good initiative, based in our Tijuana, Mexico
office, sponsors summer programs that promote software
skills development at U.S. universities for young students from
Mexico who otherwise may not get the chance to pursue
post-secondary education. Participants conduct a three-monthsoftware development project with a post-graduate studentthat culminates with a presentation of their ideas on how to
produce positive impacts through software innovation. We
continue to facilitate education and employment for many ofthese participants.
Our Tijuana office also hosts interns from local universities,
who conduct outstanding work developing software thatchanges the lives of people with diabetes. Each student
receives a mentor to facilitate their learning and development.
In 2022, we hired more than 35 interns for full-time positions.
In addition, members of the first cohort of program hires haveexcelled into leadership positions within our Tijuana software
teams. This successful program helps support our talentpipeline, stimulates the local economy through job creation,and further enhances our leadership in software development.

At Insulet, we are privileged to have employees who truly care about our
mission to improve the lives of people with diabetes. Many of our employees
have a personal connection to diabetes and reflect their commitment to our
mission in their work. We have a responsibility to shape a culture thatmaximizes the impact of our exceptional employees. In 2022, we hired a Headof Organizational Development as part of our Talent and Organizational
Development Center of Excellence to provide a dedicated focus on fostering a
positive culture and an engaging employee experience. We also continued toconcentrate on enhancing workplace flexibility while utilizing our renewedability to gather in-person to foster connections among our employees. We
continue to build an inspired, empowered, and inclusive culture where ourpeople love what they do and have fun achieving remarkable results.
Flexibility during the workday can be life-changing for caregivers and thosemanaging health challenges—situations that our customers face—and weknow that both remote and in-person arrangements can enable highproductivity. Although we were able to increase in-office work in 2022, we
continued our commitment to flexibility through our Future of Work program.
Our sustained support enables access to a broader, more diverse, and more
exceptional talent pool. To facilitate connections, we still took advantage ofthe opportunity to celebrate our culture together in-person in 2022 throughevents such as Quality and Compliance Week, hosted at our Acton,
Massachusetts headquarters, while retaining virtual offerings that are
valuable for connecting employees around the world. We strive to instill a
sense of belonging among our employees while championing flexible working
conditions that improve their wellbeing.
In 2023, we plan to refresh our values and guiding principles to engage
employees around the world and align behaviors and ways of working to
optimize our effectiveness. We believe this will foster cross-functional connectivity
to ultimately enhance our employee engagement, reputation, and community
impact amid a dynamic talent environment. Although we are constantly seeking
ways to enhance our culture, we are proud to have been recognized byorganizations around the world as a positive place to work. For more informationon our culture awards, please see the 2022 Performance section.

In 2022, we offered approximately 190 training
programs and sessions, and employees andcontractors across Insulet completed over
125,500 training hours, for an average of 27hours of training per individual.

40

Insulet 2022 Sustainability Report

Employee Engagement

Benefits

Employee feedback is an integral part of our talent management approach,and we deeply value continuous and robust dialogue with our employees.
Regular employee surveys capture the attitudes of our workforce while
enabling our culture to evolve and reflect the changing needs and diverse
perspectives of our global, multi-generational teams. In 2022, we launched
the Global “Your Voice” survey to all employees and established a regularrhythm of pulse surveys throughout the year. We conducted three surveys:
two short surveys for all employees and a third for people managers.

We offer a competitive and comprehensive global benefits program designed
to support our employees’ physical, mental, and financial wellness. Each year,
we employ external expertise to review and benchmark our global benefits
positioning to confirm that we remain competitive in each local market. As partof our external engagement, a third party evaluates the effectiveness,
equitability, and competitiveness of our compensation strategy. Annual
increases are incorporated as part of our performance review and development
process to incentivize, retain, and motivate our employees. Ultimately, we want
our benefits offerings to uphold employee trust, meet their expectations, andallow them to lead fulfilling lives, both inside and outside of work.

Our surveys helped us to identify specific opportunities to implement
programs and better support employees. For example, we developed the“Ignite Your Growth” career development program, which equips managers
to have robust development conversations with their teams and enables
employees to form individual career development plans. Our overall
engagement scores are on par with peer companies, and we excel in specificareas such as company purpose, prospect for the future, and confidence in
our leadership. In particular, we received very favorable feedback regarding
our flexible working model. We will continue with the same survey cadence in2023 to capture progress and identify additional areas in which we can
support employee success.

Insulet’s global core benefit offerings for full-time employees typically include
the following:z

 edical, dental, and visionM
insurancezLife and disability insurancezzAdditional engagement efforts include:z own Hall Meetings: Our Executive Leadership Team and functionalT
leadership teams conduct regular global Town Hall meetings todisseminate timely business updates to our employees.

z“ Stay Connected” Initiative: Leaders around the world foster
international connection among employees working virtually throughmonthly virtual networking meetings with our executives, such as Corner
Office Conversations. We also utilize various technology platforms,
including the social networking tool Yammer, to engage employees
around the world.

zThe Insider Newsletter: Our monthly global employee newsletter, The
Insider, publishes a timely collection of high-level developments and local
highlights from across our organization.

z

z

z

Employee assistance programz ou Make the DifferenceYrecognition programRetirement savings plansz aid time off and leave ofP
absence benefits

 lobal Flexible Working
G
Arrangement Policyz mployee stock purchaseEplan with a lookback feature lobal Year-End OfficeG
Closurez itness and wellness
F
programs

 rofessional certification andPtuition reimbursement

Most employees can view and change their benefits online and have access toour Human Resources Shared Services function for assistance with benefits.
Employees in the U.S. have access to benefit concierge services through our
Insulet Benefits Service Center. Additionally, in the U.S., we offer paid leave formilitary and first responders to provide the flexibility needed for these valued
employees to take time off during periods of service, training, and certification.
In 2022, we focused on enhancing the global alignment of our benefits
programs. We look forward to continuing this effort in 2023 as we hire more
employees, including at our new manufacturing facility in Malaysia.
We monitor our compensation approach to reflect our diversity values andevaluate a variety of factors when reviewing pay equity, including role,
geography, years of industry-related experience, performance, and tenure.
This includes an internal review by our Global Benefits and Compensationteam to evaluate and address discrepancies where appropriate.

41

Insulet 2022 Sustainability Report

Our DEI Vision
We are committed to creating a diverse and inclusive global
culture that reflects the diversity of the customers we serve andcreates an environment where all employees feel welcomed,
respected, and valued.

Diversity Training
We expect every Insulet employee to uphold ourcommitment to DEI. Training enables our employees
to internalize our values and mitigate the risk of bias inour business relationships and interactions. In 2022,
we launched our flagship diversity training, Conscious
Inclusion, to all employees across Insulet and achieved

Our diversity strategy is managed by our Talent and Organizational Development
Center of Excellence and is championed by our Diversity Council, which iscomprised of cross-functional leadership. DEI activities focus on four mainareas—Attraction, Talent Development, Culture, and External Engagement—
which reflect our commitment to integrating DEI within our business processes.

Diversity, Equity, and Inclusion (DEI)
We believe that we can best serve our customers if our workforce reflects
the communities in which we operate. We work to recruit, retain, and equip
a diverse workforce with the skills, resources, and career advancement
opportunities to succeed. We are proud to celebrate the diversity ofexperiences, perspectives, and backgrounds that our employees bring
to work, and we believe that diversity fuels our thoughtful innovation.
By creating a culture of belonging and inclusivity, we foster innovation,
collaboration, and a positive employee experience. With this in mind,
we continue to embed diversity and inclusion practices into our culture.

Our Diversity Strategy
In 2022, we continued to develop a comprehensive, multi-year diversity andimpact strategy that outlines how to implement our greatest opportunities for
impact in alignment with the needs of our stakeholders and diversity maturity
model. Our efforts center around engaging employees from all backgrounds
and experiences to work toward our vision. We will continue to strive to inspire
our employees in the relentless pursuit of equality, health, and innovation.

In 2022, we worked to embed diversity more formally into our talentacquisition process to attract a more diverse pool of candidates. Our Diversity
and Talent Acquisition teams collaborate closely to promote recruiting andhiring practices that are fair and inclusive, and members of our Employee
Resource Groups (ERGs) from across the Company participated in recruiting
events in 2022. We also leverage our ERGs for candidate referrals. Additionally,
we incorporate diversity considerations into our succession planning efforts.
We recognize that our journey is never finished, and we intend to continuallyseek opportunities to effectively champion diversity, belonging, and inclusion
within our Company and our communities. As our diversity strategy matures,
we plan to build upon our foundation to develop new initiatives that promotethoughtful employee engagement and further embed a culture of inclusion
into our organization.
Overall, our global gender diversity is strong, with a workforce comprised of
53% male and 47% female employees in 2022,[1] and our U.S. workforce ismade up of 63% white and 37% ethnically diverse individuals. In 2022, 42% of
our global hires were female. In the U.S., the percentage of ethnically diverse
hires increased to 47%. We seek to continuously improve our talent attraction
efforts to engage a more diverse talent pool.
[1] Gender data is not collected for Austria, Germany, and Switzerland due to country data privacy
laws, so these employees have been excluded from the data.

100% participation. This established a foundational
program and set a clear expectation and commitment
to fostering an environment where everyone feels they
belong and are welcomed and respected. In addition,
we expanded our inclusive hiring training to include
hiring managers and all recruiters. We also introduced aharassment prevention training module that demonstrates
the importance of mutual respect and avoiding thenegative impacts of bias. Looking forward, we plan to
conduct Company-wide mandatory training for all
employees and contractors to continue to strengthen
the appreciation for DEI among our workforce.

42

Insulet 2022 Sustainability Report

2022 Gender Diversity by Employee Category[2]FemaleMale

Board of Directors

47%

of our global workforce
was female in 2022

2020

50%

50%

2021

50%

50%

2022

56%

44%

Executives
2020

27%

73%

2021

27%

73%

36%

64%

2020

33%

67%

2021

39%

61%

2022

41%

58%

2020

51%

49%

2021

51%

49%

2022

50%

50%

2022

Management[3]Percentage of Ethnic Diversity in the U.S.[1]
37%
33%

Staff

[2] All temporary employees have been excluded from the data. Gender data is not collected forAustria, Germany, and Switzerland due to country data privacy laws, so these employees havebeen excluded from the data. Data reflects our employees as of December 31, 2022.
2021

2022

[1] All temporary employees have been excluded from the DEI data. Data reflects our employees
as of December 31, 2022.

[3] 1% of management-level employees chose not to disclose their gender in 2022.

43

Insulet 2022 Sustainability Report

Employee Resource Groups

Workplace Health and Safety

Our ERGs are employee-led groups that foster diversity at Insulet throughsupport, education, social connection, and professional development. We also
leverage our ERGs to deepen our connection to our communities and drive
impact. In 2022, over 550 employees, representing more than 20% of ourfull-time employee population, enriched diversity and inclusion at Insulet byparticipating in at least one of our eight ERGs. Our employees spearheaded theformation of an Asian and Pacific Islander ERG in 2022, and employees continue
to submit new ideas every year. Each ERG maintains one or more executive
sponsors, has a clear charter, and receives dedicated financial support for its
actions. Our ERGs include the following:

One of our top priorities is supporting the health and safety of our workforce.
We have a responsibility to our employees and contractors around the globe
to maintain robust policies and programs that keep them safe at work eachday. By creating a healthy and safe work environment, we enable our global
workforce to stay focused on developing innovative technologies that, inturn, support the health of our customers.

zAfrican Descent ERGzAsian and Pacific Islander ERG

zHispanic/Latin ERG

z

OmniPRIDE ERGz

Sustainability ERG

z

Veterans and First Responders ERG

z

Women@Insulet Network (WIN) ERGz

Young Professionals ERG

In 2022, our ERGs hosted a number of events, including panels, webinars,
discussions, and celebrations of awareness and cultural heritage months
such as Black History Month, Women’s History Month, Earth Month, Pride
Month, and Hispanic Heritage Month. For more information on how our
ERGs positively contribute to our communities, please see the Community
Engagement section. We are committed to future support for our ERG
initiatives to reach even more employees.

Health and Safety Management Programs
As our operations and manufacturing grow in scale, it is more important thanever that we minimize health and safety risks to protect the wellbeing of ouremployees and contractors. To accomplish this, we maintain an occupational
health and safety management system which covers all our employees,
contractors, and temporary workers. This system helps us to improve oursafety performance, even as we expand the size, scope, and capabilities ofour manufacturing facilities to align with customer demand for our products.
Our Health and Safety Compliance Manual provides employees with the tools
needed to identify and report hazards and reduce work-related injuries. Our
programs and policies comply with applicable local, regional, and federallaws, including U.S. Occupational Safety and Health Administration (OSHA)
requirements. We continuously monitor and adapt to regional regulations as
we expand our facilities into new geographies. In addition to hazard
recognition, our workplace health and safety programs cover ergonomics,
hearing conservation, fall protection, and accident and injury prevention.
Furthermore, our Acton, Massachusetts facility maintains an Emergency
Action Plan that describes procedures that employees should follow when
faced with a variety of unexpected health and safety events.
We continue to maintain policies, resources, and screening procedures toprotect our employees and contractors against COVID-19 exposure. For more
information, please see the Talent Management and Retention section.

44

Insulet 2022 Sustainability Report

Health and Safety Employee
Training and Engagement
Employee involvement and feedback improve our safety programs andperformance. Manufacturing employees are required to participate in safety
training, which covers how to recognize hazards and prevent injuries specificto their job function. In 2022, we began offering supplemental trainings eachmonth on a variety of health and safety topics.
Modern manufacturing enables efficiency and automation, which reduces
exposure to health and safety risks throughout the production process. At our
Acton, Massachusetts facility, equipment is fully automated to minimize human
involvement in the operations of machines and therefore reduce the risk of
injury. We continue to maintain high standards for workplace safety, and ourorientation for technicians includes training about safe procedures. As needed,
we provide retraining and additional supervision to support compliance. In
addition, we conduct periodic health and safety audits of our facilities to monitor
the effectiveness of our programs and drive continuous improvement in ouroverall safety performance as the Company expands in size and impact.

Health and Safety Performance
Total Recordable Incident Rate (TRIR)
for employees and contractors[1]Our robust health and safety culture is informed by well-defined risk andincident reporting channels, and we encourage employees to proactively
discuss health and safety risks with their managers. In 2023 and beyond,we plan to continue to increase opportunities for employee training andengagement to further strengthen our health and safety culture. In 2022, welaid the groundwork for a cross-functional Safety Committee to review any
potential or actual health and safety incidents and make recommendations
to improve our policies and procedures. The committee is comprised of arotating group of representatives from functions such as Manufacturing,Internal Audit, and Packaging, with a focus on diverse perspectives. We
formally established the committee in early 2023, and we plan to expand
the membership and commitments of this team in the future.

Number of Injuries for Employees and Contractors[3]Days Away, Restricted, or Transferred (DART)
rate for employees and contractors[2]

1.01

1.01

10
0.59

8

8

2021

2022

0.29

2021

2022

[1] This figure only includes employees and contractors at our Acton, Massachusetts facility.
We started disclosing TRIR and DART rate for employees and contractors in 2021.
[2] This figure only includes employees and contractors at our Acton, Massachusetts facility.
We started disclosing TRIR and DART rate for employees and contractors in 2021.

2020

[3] T
 his figure only includes employees and contractors at our Acton, Massachusetts facility.

Zerorecorded incidents ofwork-related ill healthor fatalities in 2022

100%
of our workers are covered byan occupational health andsafety management system

45

Insulet 2022 Sustainability Report

Community Engagement
Beyond the daily dedication to improving the lives of people withdiabetes, our employees care deeply about supporting healthiercommunities where we live and work. We facilitate opportunities forour people to further uplift and build relationships with communities
through volunteering and philanthropy. We also partner with andsupport external organizations that share our mission, reflecting ourongoing commitment to positively impact society.
Looking forward, we plan to enhance our community engagement efforts
and harness our unique body of expertise. We are evaluating ways toadvance our philanthropy and volunteering work in alignment with ourambition to fuel medical technology innovation and improve access to
education. Additionally, we intend to improve our policies and procedures
related to supporting healthier communities, implement a new corporate
giving management system, and explore opportunities to disclose moredetailed information regarding philanthropic donations.
In 2022, our community engagements included the following:zzz

 upport for Ukraine: At Insulet, we support the people of UkraineS
and the international community impacted by the war and violence in
Ukraine. In keeping with our mission of improving the lives of people
with diabetes, Insulet and our employees contributed monetary
donations to Insulin for Life’s Spare A Rose for Ukraine and the
GlobalGiving Ukraine Crisis Relief Fund to lend support for the healthand wellbeing of Ukrainians.
 oliday Toy Drive: Insulet Tijuana and San Diego teams cameH
together and held a toy drive to make the holidays brighter for local
children. Employees collected, individually wrapped, and donatedmore than 80 brand-new gifts—each to a specific child. Our Women@
Insulet Network ERG, our field sales teams in Northern California, and
our Acton, Massachusetts corporate headquarters employees also
contributed by supporting Toys for Tots.
 alvation Army’s Angel Tree Program: Continuing a holiday
S
tradition, the Acton Manufacturing team donated hundreds of toys tochildren in need.

z are Packages for Military Service Members: In April, Insulet’sC
Veterans and First Responders ERG joined forces with the United Service
Organizations (USO), the leading charitable organization in the U.S.
serving active-duty service members and military families. Insulet
volunteers assembled care packages that included snacks, toiletries, andshaving materials for deployed active-duty military personnel travelingthrough U.S. international airports.

z lothing Drive: Insulet employees from across the globe participated inCprofessional clothing drives sponsored by various agencies to support
members of our communities, including young professionals starting out
in their careers.

z orld Cleanup Day: World Cleanup Day unites millions of volunteers,Wgovernments, and organizations in 191 countries to tackle the global
waste problem and help build a sustainable world. In September, Insulet
employees in Massachusetts, Northern California, and Tijuana removed
waste from local waterways as part of the initiative.

z errimack Valley Food Bank: Insulet employees volunteered to packMfood packages for children in need near our Acton, Massachusetts
headquarters, filling over 650 bags.

z upport for Children with Diabetes: We supported the Barton CenterS
for Diabetes Education in Massachusetts and Camp Conrad Chinnock in
California as part of our efforts to foster positive connections across thediabetes community.

z our de Cure: Across the globe, our employees organized walks, runs,Tand bike rides to raise funds for the Tour de Cure, benefiting theAmerican Diabetes Association.

46

Insulet 2022 Sustainability Report

Appendix
About This Report
We are proud to present our 2022 Sustainability Report, which reflects our progress andperformance for key ESG topics. Unless otherwise noted, all reporting covers our efforts
from January 1, 2022, to December 31, 2022. This report was prepared with reference to the
Global Reporting Initiative (GRI) 2021 Standards, the Sustainability Accounting Standards
Board (SASB) Medical Equipment and Supplies Standard, and the recommendations fromthe Taskforce for Climate-related Financial Disclosures (TCFD). We welcome your questions,comments, and feedback on this report by contacting sustainability@insulet.com.

In This Section
TCFD Content Index
SASB Content Index
GRI Content Index

Introduction

Our Approach to Sustainability

Resilient Operations

Sustainable Product Innovation

People and Communities

Appendix47

Insulet 2022 Sustainability Report

TCFD Content Index
TCFD Recommendations

Insulet’s Approach

Governance

Describe the board’s oversight of climate-relatedrisks and opportunities.

Our Nominating, Governance, and Risk Committee reviews our ESG performance and reporting and maintains oversight of our risks at the highest level. Our VP of Global Sustainability
and CSO reports to the Nominating, Governance, and Risk Committee on the Company’s ESG progress and initiatives at least twice per year. Incorporating input from our Board of
Directors, our Global Sustainability function executes our strategy and tracks our performance on sustainability topics, including climate risks and opportunities.

Describe management’s role in assessing andmanaging climate-related risks and opportunities.

Our VP of Global Sustainability and CSO reports to our SVP, Global Operations, leads our sustainability strategy, and manages our ESG practices. To integrate sustainability throughout ouroperations, we collaborate across the business to reduce our environmental impacts, design innovative, sustainable products, develop an inclusive culture, and support our communities
and our customers around the world.

Strategy
We have identified climate-related risks and opportunities that may impact our business over the short, medium, and long term. These risks are not limited to but include the following:

Describe the climate-related risks andopportunities the organization has identified
over the short, medium, and long term.

Describe the impact of climate-related risks andopportunities in the organization’s businesses,
strategy, and financial planning.

Physical Risks: Insulet recognizes that climate impacts from severe weather events and chronic changing weather patterns may pose a risk to our own facilities as well as operations within
our supply chain. These changes can make accessing necessary materials for our products more challenging as well as impact the ability to produce and ship products to our global
customer base. These impacts pose a potential financial risk to the company.
Transition Risks: The impacts from climate change will not only affect physical assets and material availability but may also impact the Company from a policy and legal standpoint. Insulet
is closely monitoring any climate-related regulations, including the proposed SEC guidance, to achieve compliance. Insulet also recognizes that, as a company, we have a responsibility toconsider the implications of the climate in our business decisions, and that can pose a reputational risk to us if our customers, shareholders, or other key stakeholders do not believe ourbusiness decisions reflect that responsibility.

Insulet takes its responsibility to mitigate risk seriously, as we provide a life-changing device on which our customers rely. Our Enterprise Risk Management (ERM) team has worked
collaboratively across the company to identify our critical risks, including those present due to climate change, to ensure we have mitigation plans established.

48

Insulet 2022 Sustainability Report

TCFD Recommendations

Insulet’s Approach

Describe the resilience of the organization’s
strategy, taking into consideration different
climate-related scenarios, including a 2°C or
lower scenario.

Insulet has not yet conducted a comprehensive scenario analysis and is exploring future opportunities to do so.

Risk Management
Describe the organization’s processes for
identifying and assessing climate-related risks.

Describe the organization’s processes for
managing climate-related risks.

Describe how processes for identifying, assessing,and managing climate-related risks are integrated
into the organization’s overall risk management.

Insulet recognizes that there are both climate-related risks and opportunities, the management of which require engagement from multiple business functions and leaders. The Company
has developed an ERM program to aid in the identification, assessment, and management of enterprise-level risks. The ERM program provides a mechanism for sustainability risks andopportunities to be continuously monitored and evaluated. Insulet manages business continuity risks through our ERM team. Sustainability is a top risk area that the team continues tomonitor and evaluate for the Company. The identified physical and transition risks are considered broadly today through that process, which includes review and feedback from seniorleaders across the organization.
Within our supply chain, Insulet implements a dual local sourcing strategy and cross-qualifies suppliers to mitigate risk of impact from downtime. In the cases where we are sole-sourced due
to intellectual property rights, we manage risk through holding inventory in-house and at the supplier to ensure continuity of supply and reduced risk of disruption. To further manage ourbusiness continuity and supply chain resiliency, we utilize various risk management software tools within our supply chain and operations team. In addition, in January 2022, we acquired oneof our suppliers to bring key intellectual property and expertise in-house, strengthen our production capabilities, and mitigate supply chain risks. We take precautions to ensure that ourthird-party contract manufacturer and logistics entity safeguard our assets, including maintaining insurance, enacting health and safety protocols, and storing of computer data offsite.

Metrics and Targets

Disclose the metrics used by the organization toassess climate-related risks and opportunities inline with its strategy and risk management process.

Disclose Scope 1, Scope 2, and if appropriate,
Scope 3 GHG emissions and the related risks.
Describe the targets used by the organization to
manage climate-related risks and opportunities
and performance against targets.

Insulet is currently reviewing our carbon emissions and working to better understand the footprint from our operations and throughout our value chain. More information on our Scope 1
and 2 GHG emissions for 2022 can be found in the Climate Change and Greenhouse Gas Emissions section. We are setting our path to a net-zero economy that includes the establishmentof targets for GHG emissions reduction and increased renewable energy in our operations.

49

Insulet 2022 Sustainability Report

SASB Content Index
Disclosure

Location or Response

Affordability and Pricing

HC-MS-240a.1

Ratio of weighted average rate of net price increases (for all products) to the annual
increase in the U.S. Consumer Price Index

Data unavailable for disclosure

HC-MS-240a.2

Description of how price information for each product is disclosed to customers or totheir agents

Value, Affordability, and Accessibility

Product Safety2022 ESG Data Download
HC-MS-250a.1

Number of recalls issued, total units recalled

HC-MS-250a.2

List of products listed in the FDA’s MedWatch Safety Alerts for Human Medical
Products database2022 ESG Data Download

HC-MS-250a.3

Number of fatalities related to products as reported in the FDA Manufacturer andUser Facility Device Experience

2022 ESG Data Download

HC-MS-250a.4

Number of FDA enforcement actions taken in response to violations of current
Good Manufacturing Practices (cGMP), by type2022 ESG Data Download

We had two recalls in 2022. Please see the FDA website for more information about the recalls related to the
Omnipod DASH Insulin Management System PDM and the Omnipod 5 Controller charging mechanism.

50

Insulet 2022 Sustainability Report

Disclosure

Location or Response

Ethical Marketing

HC-MS-270a.1

Total amount of monetary losses as a result of legal proceedings associated with false
marketing claims

Data unavailable for disclosure

HC-MS-270a.2

Description of code of ethics governing promotion of off-label use of products

Marketing Practices

Product Design and Lifecycle Management

HC-MS-410a.1

Discussion of process to assess and manage environmental and human healthconsiderations associated with chemicals in products, and meet demand forsustainable products

Product Stewardship

HC-MS-410a.2

Total amount of products accepted for takeback and reused, recycled, or donated,broken down by: (1) devices and equipment and (2) supplies

Takeback Programs; 2022 ESG Data Download

Supply Chain Management

HC-MS-430a.1

Percentage of (1) entity’s facilities and (2) Tier I suppliers’ facilities participating inthird-party audit programs for manufacturing and product quality

Product Quality and Safety; Responsible Supply Chain Management

HC-MS-430a.2

Description of efforts to maintain traceability within the distribution chain

Responsible Supply Chain Management

HC-MS-430a.3

Description of the management of risks associated with the use of critical materials

Responsible Supply Chain Managementt51

Insulet 2022 Sustainability Report

Disclosure

Location or Response

Business Ethics

HC-MS-510a.1

Total amount of monetary losses as a result of legal proceedings associated withbribery or corruption

Data unavailable for disclosure

HC-MS-510a.2

Description of code of ethics governing interactions with health care professionals

Ethics, Compliance, and Anti-Corruption; Marketing Practices

Number of units sold by product category

Data unavailable for disclosure

Activity Metric
HC-MS-000.A

52

Insulet 2022 Sustainability Report

GRI Content Index
Disclosure

Location or Response

GRI Standards: General Disclosures 		
General Disclosures
GRI 2: General Disclosures 2021

2-1 Organizational details

About Insulet; 2022 10-K

GRI 2: General Disclosures 2021

2-2 Entities included in the organization’s sustainability reporting

2022 10-K

GRI 2: General Disclosures 2021

2-3 Reporting period, frequency and contact point

About This Report; Insulet’s Sustainability Report is prepared annually.

GRI 2: General Disclosures 2021

2-4 Restatements of information

We have provided restatements for data where applicable to reflect more accurate and comprehensive
data. We continue to enhance our data collection and validation processes. In 2022, Insulet completed
one acquisition that resulted in restatements of information. We acquired assets from Dynalloy, Inc., now
known as Insulet Irvine, related to the design and manufacturing of wire assemblies.

GRI 2: General Disclosures 2021

2-5 External assurance

Insulet did not seek external assurance for the 2022 Sustainability Report.

GRI 2: General Disclosures 2021

53

Insulet 2022 Sustainability Report

Disclosure

Location or Response
About Insulet; Responsible Supply Chain Management; 2022 10-K; 2022 ESG Data Download
In 2022, Insulet sold our products in the following countries:

GRI 2: General Disclosures 2021

2-6 Activities, value chain, and other business relationshipszAustraliazAustriaz

Belgiumz

Canadaz

Croatiaz

Denmarkz

Finlandz

FrancezGermanyz

Greecez

Icelandz

Israel

z

Italy

z

KuwaitzNetherlandsz

Norway

z

Qatar

z

Saudi Arabiaz

Swedenz

Switzerlandz

Turkeyz

United Arab Emiratesz

United KingdomzUnited States

54

Insulet 2022 Sustainability Report

Disclosure

Location or Response

GRI 2: General Disclosures 2021

2-7 Employees

Diversity, Equity, and Inclusion; 2022 ESG Data Download

GRI 2: General Disclosures 2021

2-8 Workers who are not employees

2022 ESG Data Download

GRI 2: General Disclosures 2021

2-9 Governance structure and composition

Our Board of Directors; 2023 Proxy Statement

GRI 2: General Disclosures 2021

2-10 Nomination and selection of the highest governance body

Our Board of Directors; 2023 Proxy Statement

GRI 2: General Disclosures 2021

2-11 Chair of the highest governance body

Our Board of Directors; 2023 Proxy Statement

GRI 2: General Disclosures 2021

2-12 Role of the highest governance body in overseeing themanagement of impacts

Our Board of Directors

GRI 2: General Disclosures 2021

2-13 Delegation of responsibility for managing impacts

ESG Governance

GRI 2: General Disclosures 2021
GRI 2: General Disclosures 2021

2-14 Role of the highest governance body in sustainability reporting

ESG Governance

GRI 2: General Disclosures 2021

2-15 Conflicts of interest

Code of Business Conduct and Ethics; Corporate Governance Guidelines
Our Board of Directors; 2023 Proxy Statement

GRI 2: General Disclosures 2021

2-16 Communication of critical concerns

Insulet does not currently report the number and specific nature of critical concerns communicated to
the Board of Directors. However, the Board of Directors reviews issues related to Insulet’s businessstrategy during each meeting.

GRI 2: General Disclosures 2021

2-17 Collective knowledge of the highest governance body

ESG Governance

GRI 2: General Disclosures 2021

2-18 Evaluation of the performance of the highest governance body

Our Board of Directors

GRI 2: General Disclosures 2021

2-19 Remuneration policies

2023 Proxy Statement

55

Insulet 2022 Sustainability Report

Disclosure
GRI 2: General Disclosures 2021

Location or Response
2-20 Process to determine remuneration

2023 Proxy Statement; Talent and Compensation Committee Charter
2023 Proxy Statement

GRI 2: General Disclosures 2021

2-21 Annual total compensation ratio

Insulet discloses the annual total compensation ratio, but does not currently disclose the ratio of thepercentage increase in annual total compensation for the organization’s highest-paid individual to themedian percentage increase in annual total compensation for all employees.

GRI 2: General Disclosures 2021

2-22 Statement on sustainable development strategy

Message from the CEO

GRI 2: General Disclosures 2021

2-23 Policy commitments

Ethics, Compliance, and Anti-Corruption; Human Rights; Supplier Code of Conduct;
Climate Change and Greenhouse Gas Emissions

GRI 2: General Disclosures 2021
GRI 2: General Disclosures 2021

2-24 Embedding policy commitments

Ethics, Compliance, and Anti-Corruption

GRI 2: General Disclosures 2021

2-25 Processes to remediate negative impacts

Ethics, Compliance, and Anti-Corruption

GRI 2: General Disclosures 2021

2-26 Mechanisms for seeking advice and raising concerns

Ethics, Compliance, and Anti-Corruption

GRI 2: General Disclosures 2021

2-27 Compliance with laws and regulations

Insulet does not currently disclose this information.

GRI 2: General Disclosures 2021

2-28 Membership associations

About Insulet

GRI 2: General Disclosures 2021

2-29 Approach to stakeholder engagement

Stakeholder Engagement

GRI 2: General Disclosures 2021

2-30 Collective bargaining agreements

Insulet respects freedom of association. We do not currently disclose the number of employees
represented by collective bargaining agreements.

56

Insulet 2022 Sustainability Report

Disclosure

Location or Response

Material Topics
3-1 Process to determine material topics

Materiality

3-2 List of material topics

Materiality

GRI 3: Material Topics 2021

3-3 Management of material topics

Stakeholder Engagement

Self-Selected Metric

Shareholder outreach2022 ESG Data Download

GRI 3: Material Topics 2021

3-3 Management of material topics

Governance and Ethics

Self-Selected Metric

Board diversity by gender, race, and/or ethnicity

Governance and Ethics; Diversity, Equity, and Inclusion; 2023 Proxy Statement

GRI 3: Material Topics 2021

3-3 Management of material topics

Ethics, Compliance, and Anti-Corruption

GRI 205: Anti-Corruption 2016205-2: Communication and training about anti-corruption
policies and procedures

Ethics, Compliance, and Anti-Corruption

GRI 3: Material Topics 2021
GRI 3: Material Topics 2021
GRI 3: Material Topics 2021
GRI Standards: Topic-Specific Disclosures
Stakeholder Management

Governance and Ethics

Compliance and Anti-Corruption

57

Insulet 2022 Sustainability Report

Disclosure

Location or Response

Data Privacy and Cybersecurity
GRI 3: Material Topics 2021

GRI 418: Customer Privacy 2016

3-3 Management of material topics

418-1: Substantiated complaints concerning breaches of customer privacy
and losses of customer data

Data Privacy and Cybersecurity
We continue to enhance our global privacy programs to meet or exceed new and expanding regulatory
requirements for privacy and data protection around the world. Details are confidential.
In early January 2023, we reported one data breach. Please see the U.S. Department of Health andHuman Services website for further information.

Marketing Practices
GRI 3: Material Topics 2021

3-3 Management of material topics

Marketing Practices

GRI 417: Marketing and Labeling 2016

GRI 417-1 Requirements for product and service information and labelingMarketing Practices

GRI 417: Marketing and Labeling 2016

GRI 417-2: Incidents of non-compliance concerning product and service
information and labeling

GRI 417: Marketing and Labeling 2016

Marketing Practices; 2022 ESG Data Download
We received zero warning letters in 2022.
Marketing Practices; 2022 ESG Data Download

GRI 417: Marketing and Labeling 2016

GRI 417-3: Incidents of non-compliance concerning marketing communications
We received zero warning letters in 2022.

Human Rights
GRI 3: Material Topics 2021

3-3 Management of material topics

Human Rights

58

Insulet 2022 Sustainability Report

Disclosure

Location or Response

Climate Change
GRI 3: Material Topics 2021

3-3 Management of material topics

Climate Change and Greenhouse Gas Emissions

GRI 305: Emissions 2016305-1: Direct (Scope 1) GHG emissions

Climate Change and Greenhouse Gas Emissions; 2022 ESG Data Download

GRI 305: Emissions 2016305-2: Energy indirect (Scope 2) GHG emissions

Climate Change and Greenhouse Gas Emissions; 2022 ESG Data Download

GRI 305: Emissions 2016305-3 Other indirect (Scope 3) GHG emissions

We are working to better understand our Scope 3 emissions to report this information in the future.

GRI 3: Material Topics 2021

3-3 Management of material topics

Energy Management

GRI 302: Energy 2016

302-1: Energy consumption within the organization

Energy Management; 2022 ESG Data Download

GRI 3: Material Topics 2021

3-3 Management of material topics

Waste Management

GRI 306: Waste 2020306-1: Waste generation and significant waste-related impacts

Waste Management

GRI 306: Waste 2020306-2: Management of significant waste-related impacts

Waste Management

GRI 306: Waste 2020306-3: Waste generated

Waste Management; 2022 ESG Data Download

GRI 306: Waste 2020

306-4 Waste diverted from disposal

Waste Management; 2022 ESG Data Download

GRI 306: Waste 2020306-5 Waste directed to disposal

Waste Management; 2022 ESG Data Download

GRI 305: Emissions 2016

Energy Management

Waste Management

59Insulet 2022 Sustainability Report

Disclosure

Location or Response

Water Management
GRI 3: Material Topics 2021

3-3 Management of material topics

Water Management

GRI 303: Water and Effluents 2018

303-1 Interactions with water as a shared resource

Water Management

303-3: Water withdrawal

Water Management; 2022 ESG Data Download

GRI 3: Material Topics 2021

3-3 Management of material topics

Responsible Supply Chain Management

Self-Selected Metric

Percentage of top-spend suppliers who have acknowledged that they haveread and understood the Supplier Code of Conduct

Responsible Supply Chain Management; 2022 ESG Data Download

Self-Selected Metric

Percentage of RBA VAP audit coverage for high-risk supplier facilities

Responsible Supply Chain Management

Self-Selected Metric

Percentage of in-scope employees who have completed Supplier Code of
Conduct training

Responsible Supply Chain Management; 2022 ESG Data Download

GRI 3: Material Topics 2021

3-3 Management of material topics

Product Quality and Safety

GRI 416: Customer Health and Safety 2016416-2: Incidents of non-compliance concerning the health and safety impacts ofproducts and services

2022 ESG Data Download

3-3 Management of material topics

Customer Centricity

GRI 303: Water and Effluents 2018
GRI 303: Water and Effluents 2018
Responsible Supply Chain Management

Product Quality and Safety

Customer Centricity
GRI 3: Material Topics 2021

60

Insulet 2022 Sustainability Report

Disclosure

Location or Response

Innovation, Research and Development, and Intellectual Property
GRI 3: Material Topics 2021

3-3 Management of material topics

Innovation, Research and Development, and Intellectual Property

Self-Selected Metric

Patents held

2022 ESG Data Download

Self-Selected Metric

Patent applications pending

2022 ESG Data Download

GRI 3: Material Topics 2021

3-3 Management of material topics

Product Stewardship

Self-Selected Metric

Total number of Pods accepted for takeback

2022 ESG Data Download

Self-Selected Metric

Total weight of Pod materials accepted for takeback (metric tons)

2022 ESG Data Download

GRI 3: Material Topics 2021

3-3 Management of material topics

Value, Affordability, and Accessibility

Self-Selected Metric

U.S. average monthly copay

Value, Affordability, and Accessibility; 2022 ESG Data Download

GRI 3: Material Topics 2021

3-3 Management of material topics

Policy and Advocacy

GRI 415: Public Policy 2016415-1: Political contributions

2022 ESG Data Download

Product Stewardship

Affordability and Accessibility

Policy and Advocacy

61

Insulet 2022 Sustainability Report

Disclosure

Location or Response

Talent Management and Retention
GRI 3: Material Topics 2021

3-3 Management of material topics

Talent Management and Retention

GRI 401: Employment 2016

401-2: Benefits provided to full-time employees that are not provided totemporary or part-time employees

Talent Management and Retention

GRI 404: Training and Education 2016404-1 Average hours of training per year per employee

Talent Management and Retention; 2022 ESG Data Download

GRI 404: Training and Education 2016
GRI 404: Training and Education 2016404-2: Programs for upgrading employee skills and transition assistanceprograms

Talent Management and Retention

GRI 404: Training and Education 2016404-3: Percentage of employees receiving regular performance and careerdevelopment reviews

Talent Management and Retention

GRI 3: Material Topics 2021

3-3 Management of material topics

Diversity, Equity, and Inclusion

GRI 405: Diversity and Equal Opportunity 2016405-1: Diversity of governance bodies and employees

Diversity, Equity, and Inclusion; 2022 ESG Data Download

Inclusion and Diversity

62Insulet 2022 Sustainability Report

Disclosure

Location or Response

Workplace Health and Safety
GRI 3: Material Topics 2021

3-3 Management of material topics

Workplace Health and Safety

GRI 403: Occupational Health and Safety 2018403-1: Occupational health and safety management system

Workplace Health and Safety

GRI 403: Occupational Health and Safety 2018403-2: Hazard identification, risk assessment, and incident investigation

Workplace Health and Safety

GRI 403: Occupational Health and Safety 2018403-3: Occupational health services

Workplace Health and Safety

GRI 403: Occupational Health and Safety 2018403-4 Worker participation, consultation, and communication on
occupational health and safety

Workplace Health and Safety

GRI 403: Occupational Health and Safety 2018403-5: Worker training on occupational health and safety

Workplace Health and Safety

GRI 403: Occupational Health and Safety 2018
GRI 403: Occupational Health and Safety 2018403-6: Promotion of worker health

Talent Management and Retention

GRI 403: Occupational Health and Safety 2018403-7 Prevention and mitigation of occupation health and safety impacts
directly linked by business relationships

Responsible Supply Chain Management

GRI 403: Occupational Health and Safety 2018403-8: Workers covered by an occupational health andsafety management system

Workplace Health and Safety; 2022 ESG Data Download

GRI 403: Occupational Health and Safety 2018403-9: Work-related injuries

2022 ESG Data Download

GRI 403: Occupational Health and Safety 2018403-10: Work-related ill health2022 ESG Data Download

3-3 Management of material topics

Community Engagement

Community Engagement
GRI 3: Material Topics 2021

63

Insulet 2022 Sustainability Report

Throughout the report, we are proud to use images of real customers.
For more information, please visit: www.insulet.com and www.omnipod.com.
© 2023 Insulet Corporation. Omnipod, the Omnipod logo, Omnipod 5, DASH,
and PodPals are trademarks or registered trademarks of Insulet Corporation.
All rights reserved. All other trademarks are the property of their respective
owners. The use of third-party trademarks does not constitute an
endorsement or imply a relationship or other affiliation.

64